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INTRODUCTION 
 
Labour is characterized by forceful and painful uterine contractions that results 
in cervical dilatation and fetal descend through the birth canal.1 
 
Active labour can be reliably diagnosed when there is an effective uterine 
contraction associated with dilatation of cervix of 3 cm or more. Most women in 
spontaneous labour irrespective of parity index will deliver within approximately 
ten hours after admission for spontaneous labour.2 
 
There are several labour abnormalities that may interfere with the orderly 
progression to spontaneous delivery. This is referred to as Dystocia.3 Almost 50% 
of labour are felt to be affected by dystocia in the first or second stages of labour 
and this particularly affects the first labour.4 
 
Prolonged labour is an important risk factor for both maternal morbidity and 
perinatal compromise.5 Minimizing the duration of labour without compromising 
fetomaternal wellbeing is a desirable outcome in all labour and delivery units. 
 
More than 30 years ago, O’drisoll and associates (1984) pioneered the concept 
that a disciplined, standardized labour management protocol reduced the number 
of caesarean deliveries for dystocia.2 
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The approach is referred to as active management of labour. Two of its 
components are widely used – amniotomy and oxytocin.2 In addition 
antispasmodic drugs have been used to accelerate cervical dilatation and thus 
reduce the labour duration. 
 
Hirsch first described the use of antispasmodic drugs to shorten the first stage of 
labour in 1937: he reported that labour duration could be decreased by 2–4 hours 
by using an atropine-like drug.6 
 
Various spasmolytic drugs have been used like atropine, valethamate bromide, 
hyoscine butyl bromide, drotaverine hydrochloride. These drugs are given in 
various routes like intravenous, intramuscular, per rectal. 
 
Since most of the prolonged labours are among the nulliparous women, the 
current study was done to compare the safety and efficacy of intravenous 
drotaverine hydrochloride against intravenous `hyoscine butyl bromide in 
augmentation of labour among nulliparous women. 
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AIM & OBJECTIVES OF THE STUDY 
 
AIM:  
To study and compare the efficacy and safety of Drotaverine hydrochloride and 
hyoscine-N-butyl bromide in the augmentation of labour among nulliparous 
women 
 
OBJECTIVES: 
1. To compare the efficacy of Drotaverine hydrochloride and Hyoscine-N 
butyl bromide in hastening cervical dilatation and thus in shortening the 
duration of labour. 
2. To compare the side effects of both the drugs on the mother. 
3. To compare the side effects of both the drugs on the newborn. 
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REVIEW OF LITERATURE 
 
 
Human Labour is a complex process and is characterized by the onset of effective 
uterine contractions leading to the progressive effacement and dilatation of cervix 
resulting in the delivery of the fetus, placenta and the membranes. 7 
 
There is extensive preparations in both the uterus and cervix long before this. 
During the initial 36-38 weeks of gestation, the uterus is in an unresponsive 
preparatory phase. Concurrently the cervix begins an early stage of remodeling- 
termed softening- yet maintains structural integrity. The onset of labour 
represents the culmination of a series of biochemical changes in both the cervix 
and  uterus1. 
 
PHASES OF PARTURITION: 
The bringing forth of parturition is an orchestrated transformations in both uterus 
and cervix which is divided into four overlapping phases. These phases of 
parturition include: (1) a prelude to it, (2) the preparation for it, (3) the process 
itself, and (4) the recovery.1 
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Fig 1: The Phases of Parturition 
 
PHASE 1 (QUIESCENCE): 
The initial phase of quiescence comprises 95% of total duration of pregnancy 
and is characterized by uterine smooth muscle tranquility along with 
maintenance of cervical structural integrity. 
 
A. Uterine Quiescence 
The inherent propensity of the myometrium to contract is held in abeyance 
and the uterine muscle is rendered unresponsive to the natural stimuli. 
Concurrently the uterus must initiate extensive changes in its size and 
vascularity to accommodate the pregnancy and prepare for the uterine 
contractions.1 
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The myometrial unresponsiveness of phase 1 continues until it reaches the 
end of 36 to 38 weeks of pregnancy. Slow low intensity myometrial 
contractions felt during the this phase called the Braxton hicks 
contractions or false labour do not normally cause cervical dilatation.1 
 
B. Cervical softening: 
The cervix has a number of  functions during pregnancy that include: (a) 
helps to protect the reproductive tract from infection by its barrier function 
(b)helps  to maintain cervical competence despite increase in gravitational 
force, and (c) orchestration of changes in extracellular matrix  that allow 
progressive increases in tissue compliance.1 
 
The first stage of remodeling in cervix named as cervical softening is 
characterized by an increase in tissue compliance although the cervix is 
firm and competent. Hegar (1895) described the softening of the lower 
segment at 4 to 6 weeks of gestation which was once used in diagnosis of  
pregnancy1. 
 
C. Structural changes with softening: 
Cervical softening is due to stromal hypertrophy, glandular hypertrophy 
and hyperplasia increased vascularity, and slow, progressive structural or 
compositional changes of the extracellular matrix.1 
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PHASE 2 (PREPARARTION FOR LABOUR): 
It is the progression of uterine changes called the uterine awakening or activation 
during the last 6 to 8 weeks and cervical ripening takes place. 
     
A. Uterine Awakening: 
The changes in the myometrium prepare it for the true labour contractions. 
This shift is due to alterations in the expression of key proteins that plays 
the role in uterine muscle contractility. This in turn leads to increase in 
uterine irritability and responsiveness to uterotonins.1 
 
Another important change is the formation of lower uterine segment from 
the isthmus. As a result descend of fetal head to or even through the pelvic 
inlet takes place. This is called lightening. 1 
           
B. Cervical Ripening: 
Cervical modifications that results in effacement and dilatation cervix 
upon the onset of effective uterine contractions which is called the cervical 
ripening. During this process of ripening the total composition and amount 
of glycosaminoglycan and proteoglycans with in the extracellular matrix 
is altered1. 
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C. Cervical Connective tissue: 
The body of uterus is predominantly smooth muscle whereas the cervix 
comprises primarily connective tissue. The cervix is an extracellular 
matrix rich tissue which includes type I, III, IV collagen, 
glycosaminoglycan, matricellular proteins, elastin and proteoglycans. 1 
 
a. Collagen: 
Collagen is largely responsible for structural disposition of the 
cervix. During cervical ripening collagen fibril diameter is 
increased and there is increased spacing between the fibrils. The 
dynamic changes in the structure of collagen rather than content of 
collagen helps in regulation of remodeling. 1 
 
b. Glycosaminoglycan (GAG): 
These are high molecular weight polysaccharides that complex with 
proteins to form glycosaminoglycan. The importance of regulated 
changes in glycosaminoglycan size during ripening and dilatation 
of cervix is supported by a study that reports administration of 
hyaluronidase to the cervix for ripening in term pregnant women. 1 
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c. Proteoglycans: 
These glycoproteins are composed of a protein core and GAG 
chains. Changes in the amount of core protein or in the number, 
length, or degree of sulfation of GAG chains can influence 
proteoglycan function. 1 
D. Inflammatory changes: 
These marked changes that takes place within the extracellular matrix 
during cervical ripening in phase 2 are accompanied by invasion of 
cervical stromal tissue with inflammatory cells. As such cervical chemo 
attractants attract inflammatory cells which in turn release enzymes that 
may help in degradation of collagen and other matrix components1. 
 
PHASE 3 (LABOUR): 
This phase is synonymous with active labour which is divided in to three 
stages. Labour is the process that leads to childbirth. It begins with the onset of 
regular uterine contractions and hence with delivery of newborn and expulsion 
of the placenta.2   
It is divided in to three stages as shown in the figure below. 
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STAGES OF LABOUR 
                                  
                               Fig 2: Stages of labour 
FIRST STAGE OF LABOUR: 
The first stage of labour also called the stage of complete cervical effacement and 
dilatation. It is measured from the onset of true labour to the complete cervical 
dilatation. It lasts for about 6 – 18 hours in a nulliparous women and 2 – 10 hours 
in parous women.8 
 
A. Uterine labour contractions: 
The uterine smooth muscle contractions during labour among all the 
physiological muscular contractions are painful. This is due to (a) hypoxia of 
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contracted myometrium, (b) nerve ganglia in the cervix and lower uterus being 
compressed, (c) cervical stretching that takes place during dilatation, and (d) 
stretching of overlying peritoneum of uterine fundus.1 
 
During active labour the anatomical uterine divisions that were initiated in phase 
3 become evident. The upper segment is firm during contractions and the lower 
segment is softer distended and more passive. The myometrium undergoes a 
process called retraction by which the upper segment does not goes back to its 
original length after contractions and hence the upper segment becomes slightly 
smaller with each successive contraction.1 
 
  B. Cervical changes: 
As a result of contraction forces effacement and dilatation occurs in the already 
ripened cervix. Effacement is taking up or obliteration of the cervix which 
becomes evident clinically by the cervical canal length shortening from 2 cm to 
a mere circular orifice with almost paper thin edges. 1 
Both the isthmus of uterus (which is the lower segment) and cervix have lesser 
resistance during a contraction a centrifugal pull is exerted on the cervix and 
creates cervical dilatation.   
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Cervical dilatation is divided two phases (a) the latent phase and (b) the active 
phase. Friedman developed the concept of three functional labour divisions to 
describe the physiological objectives of each division as shown below.2 
 
Divisions of labour: 
The three divisions are preparatory division, dilatation division and 
pelvic division. Cervical dilatation was divided into two phases. The first is the 
latent phase which happens simultaneously to the preparatory division and the 
next is active phase which corresponds to the dilatational division. Friedman 
further subdivided the active phase into three phases namely the acceleration 
phase, the phase of maximum slope, and the deceleration phase.1 
 
                  Fig 3: Cervical Dilatational curve of nulliparous women 
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Preparatory division: 
During this division of labour the cervix dilates little but its connective tissue 
components undergoes a considerable change. This initial division of labour can 
be arrested by means of sedation and conduction analgesia. 
 
Dilatational division: 
The cervix dilates at its rapid rate which is unaffected by sedation during this 
division of labour. Due to the rapidity of cervical dilatation the pattern of cervical 
dilatation is represented by a sigmoid curve during the preparatory and 
dilatational divisions of normal labour. 
 
                
                             Fig 4: Functional labour divisions 
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Pelvic division: 
This division of labour begins with the deceleration phase of cervical dilatation. 
The classic labour mechanisms that involves the cardinal fetal movements of 
cephalic presentation takes place principally during this division. 
 
SECOND STAGE OF LABOUR: 
 
The second stage is called the stage of fetal expulsion. This stage begins with 
complete cervical dilatation and ends with delivery of fetus. The median duration 
is approximately fifty minutes for nulliparous and twenty minutes in multiparous 
but it is highly variable.2 
 
Parity – nulliparous versus multiparous and cervical dilatation at admission were 
the significant determinants of the length of spontaneous labour.2 
 
THIRD STAGE OF LABOUR: 
The third stage is called the stage of placental separation and expulsion. It begins 
with the birth of the baby and ends with the delivery of the placenta.  It takes 5 to 
30 minutes. Delivery of the placenta occurs in two stages: (a) initially placenta 
separates from the uterine wall and lies within the lower uterine segment and/or 
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the vagina and (b) following the separation the placenta is expelled out of the 
birth canal.8 
 
PHASE 4 (PUERPERIUM): 
After the delivery of the placenta the myometrium remains in a stage of rigid 
and persistent contraction and retraction. Involution of uterus and cervical repair 
both remodelling processes that helps to bring back these organs to non-pregnant 
state follow in a timely fashion. This usually takes place for a period of 4 to 6 
weeks after birth. 
 
PYSIOLOGICAL PROCESSES REGULATING PARTURITION1 
 
There are two theories proposed for labour initiation. They are (a) functional loss 
of pregnancy maintenance factors and (2) synthesis of factors that induce 
parturition. Both rely on careful regulation of smooth muscle contraction. 
MYOMETRIAL ACTION: 
Anatomical and physiological considerations: 
The characteristics of smooth muscle which are unique to it confer advantage for 
uterine contraction efficiency and fetal delivery. They are 
 
i. The degree of smooth muscle shortening with contractions may  
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be one order of magnitude greater than in striated muscle. 
 
ii. The forces can be exerted in smooth muscle in multiple directions. 
 
iii. The smooth muscle is not organized in the same manner as 
skeletal muscle. 
 
iv. Greater multidirectional force generation in the uterine fundus 
compared with that of the lower uterine segment permits versatility 
in expulsive force directionality. 
 
Regulation of myometrial contraction and relaxation: 
 
Uterine smooth muscle contraction is controlled by transcription of key genes that 
produce proteins that are capable of either repressing or enhancing cellular 
contractility. 
i. Actin myosin interactions:  This interaction is essential for muscle 
contraction. It is necessary that actin gets converted to a filamentous 
form from globular form. This in turns activates adenosine 
triphosphate which hydrolysis and generates energy. This is 
catalyzed by myosin light chain kinase which is activated by 
calcium. 
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ii. Intracellular Calcium: Agents that promote myometrial 
contraction increase intracellular calcium through voltage or ligand 
regulated calcium channels or releases calcium from sarcoplasmic 
reticulum. Conditions which decrease intracellular calcium can 
cause relaxation 
 
iii. Myometrial Gap junctions: Intracellular junctional channels 
helps in transferring cellular signals which controls contraction and 
relaxation of myometrium. These are called connexons. Four 
described in uterus are 26, 40, 43, and 45. 
 
iv. Cell surface receptors: The three major cell surface receptors that 
can directly regulate myometrial contractile state are ion channel 
linked, G protein linked and enzyme linked. 
 
CERVICAL DILATATION DURING LABOUR 
 
There is a large influx of leucocytes into the cervical stroma with dilatation of 
cervix. The cervix must undergo a state of reorganization to recover to the initial 
non-pregnant status by the rapid removal of the connective tissue which was 
necessary for the ripening and dilatation of cervix. 
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BIOCHEMICAL PROCESSES REGULATING PARTURITION1 
PHASE 1: UTERINE QUIESCENCE AND CERVICAL COMPETENCE 
It is induced by multiple independent and cooperative bio molecular processes. 
A. Actions of estrogen and progesterone via intracellular receptors: 
The increase in the ratio of progesterone to estrogen is responsible for 
maintenance of pregnancy and a fall in the ratio is responsible for 
parturition. 
 
B. Myometrial cell to cell communications: 
Progesterone maintains uterine quiescence by decreased expression of the 
contraction associated proteins. It promotes the expression of inhibitory 
transcription factor ZEB1- zinc finger E box binding homeobox protein 1 
which in turn inhibit the expression of CAP genes, connexon 43 and 
oxytocin receptors. 
 
C. G Protein coupled receptors: 
These receptors with appropriate ligands may act along with sex steroids 
to maintain uterine quiescence 
. 
D. Beta adrenoreceptors: 
Agents binding to these receptors have been used for tocolysis. 
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E. Luteinizing hormone and human chorionic gonadotropin receptors: 
These are increased during pregnancy than during labour. 
 
F. Relaxin: 
It mediates inhibition of myometrial contraction, cervical softening, 
vaginal relaxation and lengthening of the pubic ligament. 
 
G. Corticotrophin releasing hormone: 
It appears to promote myometrial quiescence during most of the pregnancy 
and aids myometrial contractions with onset of parturition. 
 
H. Prostaglandins: 
Prostaglandins are considered uterotonins and are produced using plasma 
membrane–derived arachidonic acid, which is produced from the 
membrane phospholipids by the action of the phospholipases A2 or C on it. 
Arachidonic acid acts as substrate for both cyclooxygenase-1 and -2—
COX-1 and 2 also called as type 1 and type 2 prostaglandin H synthase—
PGHS-1 and -2.  
 
Both PGI2 and   PGE2 helps  to maintain uterine quiescence by increasing 
cAMP signaling, yet PGE2 can promote uterine contractility through 
binding to EP1 and EP3 receptors. And also, PGE2, PGD2, and PGI2 can 
also cause vascular smooth muscle relaxation and vasodilatation in many 
circumstances. 
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Expression of COX-2 seems to be spatially regulated in both myometrium 
and cervix in pregnancy and labor with concentration gradient increasing 
from the fundus to the cervix. 
 
I. Atrial natriuretic peptide: 
Guanyl cyclase activation increases intracellular cGMP levels, which also 
promotes smooth muscle relaxation. Both atrial natriuretic peptide (ANP) 
and brain natriuretic peptide (BNP) receptors stimulates intracellular 
cGMP levels which are both present in pregnant myometrium. 
 
J. Accelerated uterotonins degradation: 
Myometrial cell refractoriness is stimulated by pregnancy induced 
compounds and enzymes that degrade or inactivate endogenously 
produced uterotonins which shows a striking increase during pregnancy. 
 
Some of these and their degradative enzymes include PGDH, which 
degrades prostaglandins; enkephalinase and endothelins; oxytocinase and 
oxytocin; diamine oxidase and histamine; catechol O-methyltransferase 
and catecholamines; angiotensinases and angiotensin-II; and platelet-
activating factor (PAF) acetylhydrolase and PAF. 
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PHASE 2: UTERINE ACTIVATION AND CERVICAL RIPENING: 
A. Classical Progesterone withdrawal and parturition 
 
B. Progesterone receptor antagonist 
 
C Functional progesterone withdrawal 
i.Changes in the relative expression of the nuclear progesterone 
receptor (PR) protein isoforms, PR-A, PR-B, and PR-C 
ii.Changes in the relative expression of membrane-bound 
progesterone receptors 
iii.Posttranslational modifications of the progesterone receptor 
iv.Alterations in progesterone receptor activity through changes in 
the expression of co-activators or co-repressors that directly 
influence receptor function 
v.Local inactivation of progesterone by steroid-metabolizing 
enzymes or synthesis of a natural antagonist. 
vi.Micro RNA regulation of progesterone metabolizing enzymes. 
 
D. Oxytocin receptors 
Estradiol and progesterone are the primary regulators of oxytocin receptor 
expression. One of the mechanisms is through the inhibition of myometrial 
oxytocin response whereby progesterone maintains uterine quiescence. 
E. Relaxin  
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These include remodeling of the extracellular matrix of the breast, pubic 
symphysis, vagina, cervix and uterus as well as promoting cell proliferation 
and inhibiting apoptosis. 
 
F. Fetal Contributions to Initiation of Parturition 
i. Uterine stretch and parturition. 
ii .Fetal endocrine cascades leading to parturition. 
iii. Placental corticotrophin releasing hormone production. 
iv. Corticotrophin releasing hormones and parturition timing 
 
PHASE 3: UTERINE STIMULATION: 
Increased uterotonin production takes place once phase 1 is suspended and uterine 
phase 2 processes commences. Uterotonins that are responsible for labor 
induction include oxytocin, prostaglandins, PAF, serotonin, angiotensin II, 
histamine, and many others. 
A. Role of Oxytocin in Phases 3 and 4 of Parturition 
Oxytocin was logically suspected in parturition initiation because of 
successful labor induction with it. 
i. The increase in the number of oxytocin receptors in myometrial 
and decidual tissues nearing term. 
ii. Oxytocin acts on decidual tissue and there by promotes release 
of prostaglandins. 
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iii. Oxytocin is synthesized directly in decidual and extraembryonic 
fetal tissues and in the placenta 
 
B. Prostaglandins in Phase 3 of parturition: 
Evidence which supports this theory includes: 
i. Levels of prostaglandins—or their metabolites are found to be 
increased in amniotic fluid, maternal plasma, and maternal urine 
during labor. 
ii. Treatment of pregnant women with prostaglandins causes 
abortion or labor at any stage of gestation., by any of several 
routes of administration. 
iii. Administration of COX 2 inhibitors to pregnant women will 
cause a delay in the onset of spontaneous labor and sometimes 
arrest preterm labor. 
iv. Prostaglandin treatment of myometrial tissue in vitro sometimes 
causes contraction, dependent on the prostanoid tested and the 
physiological status of the tissue treated. 
 
C. Endothelin 1 
These induce myometrial contraction powerfully. 
  
D. Angiotensin II 
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ABNORMAL LABOUR 
 
Dystocia literally means difficult labour and is characterized by abnormally slow 
labour progress.3 Globally a significant number of labour require obstetric 
intervention and the commonest reason is dysfunctional labour.4 
 
The difference between primigravid and multigravid labour are (mother 
important clinically and relate to the differences in the four ‘P’s’- Patient 
(mother), Powers, Passenger (fetus), Passage. Women undergo a unique 
psychological experience in their first labour and this is affected by the perception 
of pain, level of hydration, mobility, etc.4 
 
In the terms of the power, uterine activity in the primigravida is relatively 
inefficient and the labour is longer. The primigravida uterus will exhibit ‘inertia’ 
as labour becomes prolonged.4 
 
Obstetric management in labour dystocia in primigravida women requires a 
combination of experience, science, and art with the primary aim of avoiding 
operative delivery whenever possible.4 
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Table 1: Common Clinical Findings in Women with Ineffective Labour 
 
Inadequate cervical dilatation or fetal descent 
Protracted labour—slow progress 
Arrested labour—no progress 
Inadequate expulsive effort—ineffective "pushing" 
Fetopelvic disproportion 
Excessive fetal size 
Inadequate pelvic capacity 
Malpresentation or position of fetus 
Ruptured membranes without labour 
 
 
Dystocia, especially if labour is prolonged is associated with an increased 
incidence of several common obstetrical and neonatal complications. Intrapartum 
chorioamnionitis and postpartum pelvic infections are more common with 
desultory and prolonged labour. Similar to the mother the incidence of peri 
partum fetal sepsis is increased with longer labours.3 
 
The two factors that determine labour duration are uterine contractility and 
cervical dilatation rate. Active management of labour was introduced in 1960s as 
a method to prevent prolonged labour.5 
 
 36 
 
Table 2: Abnormal labour patterns. 
Abnormal Labour Patterns Diagnostic Criteria 
Nulliparous Multiparous 
Prolongation disorder 
 
Prolonged latent phase 
 
>20 hr 
 
 
>14 hr 
Protraction disorders 
 
Protracted active-phase dilatation 
 
 
<1.2cm/hr 
 
 
<1.5cm/hr 
 
Protracted descent 
 
<1cm/hr 
 
<2cm/hr 
Arrest Disorders 
 
Prolonged deceleration phase  
>3 hr 
 
 
>1 hr 
 
Second arrest of dilatation 
 
>2 hr 
 
>2 hr 
 
Arrest of descent 
 
>1 hr 
 
>1 hr 
 
Failure of descent No descent in 
deceleration phase 
or second stage 
 
No descent in 
deceleration phase or 
second stage 
 
 
Various methods of cervical dilatation includes both mechanical and 
pharmacological methods. The mechanical factors are stripping of membranes, 
cervical stretching and amniotomy. Various pharmacological agents used are 
oxytocin, prostaglandins, Hyoscine, drotaverine, Valethamate.5 
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THE PARTOGRAM 
Friedman undertook a graphic-statistical analysis of nulliparous labour and 
produced his classic labour curve. This was based on a selected group of 500 
primiparous patients and has been used to define normal progress since. Labour 
progress accelerates at the point of transition from the latent phase into early 
active phase followed by linear progress at 1cm/hr.4 
      
                                         Fig 5: Labour curve among Nulliparous 
The partogram or cevicograph was described by Philpott and Castle in 1972 and 
became embedded in clinical practice worldwide. 4 
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                                                             Fig 6: Partograph 
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The partogram is the documentation of serial assessment of the cervical dilatation 
and fetal descent as soon as the active phase of labour begins. It is an easy and 
simple way of visually summarizing the progress of labour or the lack progress 
and allows early and objective identification of labour that has deviated from 
normal labour curve.9 
 
The ‘action line’ recommended by the WHO is set 4 hours to the right of an ‘alert 
line’ allowing an unambiguous diagnosis of prolonged labour and timely 
intervention. The partogram still provides an important concise overview of all 
constituents of labour. 4 
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DROTAVERINE HYDROCHLORIDE 
 
Drotaverine, a benzylisoquinoline derivative, is an effective antispasmodic drug, 
structurally related to papaverine.10 
CHEMISTRY: 
Chemical name: (Z)-1-(3, 4-diethoxybenzylidene)-6, 7-diethoxy-1, 2, 3, 
4-tetrahydroisoquinoline. 
Molecular Formula: C24H31NO4 
                            
                                         Fig 7: Chemical structure of Drotaverine Hydrochloride 
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MECHANISM OF ACTION: 
Drotaverine is an inhibitor of type IV phosphodiesterase leading to increase in 
intracellular cyclic AMP and cyclic GMP. It has mild calcium channel blocking 
effect with a direct action on smooth muscle thereby relieving smooth muscle 
spasm and cervical dilatation11. It has no anticholinergic effects. 
 
PHARMACOKINETICS: 
Absorption and distribution: 
After intravenous administration the drug distributes rapidly into every organ. It 
is 80-95% bound to plasma proteins. The half-life is 7 to 12 hrs.3 60% of the dose 
was in the bile collected during 5 hours.12  It does not cross the human placenta 
hence has no significant fetal adverse effect. 
 
Metabolism and elimination: 
The metabolism is mainly hepatic by demethylation. The drug is excreted mainly 
by nonrenal route in the bile as beta-glucuronide. During 96 hours of observation, 
67% of the radioactivity administered was found in the stools while only 20% of 
it was eliminated with urine.12 Its metabolites are more potent than drotaverine 
itself. 
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ADVERSE EFFECTS: 
Headache, vomiting, nausea, tachycardia.11 
CONTRAINDICATIONS: 
Severe renal/hepatic/cardiac dysfunction.10 
DRUG REACTIONS: 
May attenuate the action of levodopa.10 
PREPARARTION USED: 
Each ampoule contains 40mg of drotaverine hydrochloride in 2 mL aqueous 
solution 
 
Fig 8: Picture of Drotaverine ampoule 
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HYOSCINE N BUTYL BROMIDE 
Hyoscine (Scopolamine) is naturally occurring muscurinic receptor 
antagonist.13Hyoscine butylbromide a quarternary ammonium compound is semi 
synthetic derivative of Hyoscine. 
CHEMISTRY: 
Chemical name: (1S,3S,5R,6R,7S)-8-Butyl-6,7-epoxy-3-[(S)-tropoyloxy] 
tropanium bromide 
Molecular Formula: C21H30BrNO4 
                        
                                      Fig 9: Chemical structure of Hyoscine butyl bromide 
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MECHANISM OF ACTION: 
Hyoscine compete with Acetyl Choline for a common binding site on the 
muscarinic receptor. Since Hyoscine is competitive antagonist, it can be 
overcome if there is increased concentration of Acetyl Choline at muscarinic 
receptors of the effector organ.13 
 
PHARMACOKINETICS: 
Absorption and distribution: 
Hyoscine butylbromide is rapidly distributed after intravenous administration. 
(t1/2α = 4 min, t1/2β = 29 min) into the tissues. Due to its high affinity for 
muscarinic receptors and nicotinic receptors it is mainly distributed on muscle 
cells of the abdominal and pelvic area as well as in the intramural ganglia of the 
abdominal organs. It is 4.4% bound to plasma proteins. It does not cross the 
blood-brain barrier.14 
 
Metabolism and elimination: 
The main metabolic pathway is the hydrolytic cleavage of the ester bond. The 
t1/2γ or the half-life of the terminal elimination phase is 5 hours. Around 42 to 
61% of the Hyoscine is by renal excretion and 28.3 to 37% faecally. The active 
metabolites excreted in the urine (approximately 50%) bind poorly to the 
muscarinic receptors and does not have a significant clinical action.14 
 45 
 
ADVERSE EFFECTS: 
Nausea, vomiting, headache, transient tachycardia, photo-phobia.14 
CONTRAINDICATIONS: 
Myasthenia gravis, narrow angle glaucoma, tachycardia, megacolon, Paralytic 
ileus.14 
DRUG REACTIONS: 
Antidepressants, antipsychotics, anticholinergics can potentiate the 
anticholinergic effect.14 
PREPARARTION USED: 
Each ampoule contains 20 mg of hyoscine butyl bromide in 1 mL aqueous 
solution. 
                                     
            Fig 10: Picture of Hyoscine ampoule 
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The potential role of drotaverine hydrochloride and hyoscine butyl bromide in 
enhancing the progress of the first stage of labour and there by shortening the 
duration of labour has been investigated in many trials. 
 
Sharma et al (2001) did a randomized controlled trial among 150 nulliparous 
women in established labour to compare the efficacy of intramuscular drotaverine 
hydrochloride and valethamate bromide in shortening the duration of labour. 
They found both intramuscular drotaverine hydrochloride and valethamate 
bromide are effective in shortening the duration of labour; however, drotaverine 
augments labour more rapidly and is associated with less side effects.15 
 
Singh et al (2004) conducted a   double-blind placebo-controlled randomized 
study among 100 uncomplicated primigravidas in spontaneous labour to evaluate 
the efficacy of intramuscular drotaverine hydrochloride in augmentation of 
labour. They found intramuscular drotaverine hydrochloride to be safe and 
effective in augmentation of labour.16 
 
Tripti et al (2009) conducted a study among 200 low uncomplicated primigravida 
and second gravida in established labour to compare the efficacy of intramuscular 
drotaverine hydrochloride and intravenous infusion of valethamate bromide in 
augmentation of labour. They found intramuscular drotaverine hydrochloride is 
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safe and more effective than intravenous infusion of valethamate in shortening 
the duration of labour. 17 
 
Madhu et al (2010) conducted a   prospective randomized study among 146 low 
risk women in spontaneous labour to compare the efficacy of intramuscular 
drotaverine hydrochloride and valethamate bromide in augmentation of labour. 
They found intramuscular drotaverine hydrochloride to be superior to 
valethamate with fewer side effects in augmentation of first stage of labour. 18 
 
Sudhir Babu Palii et al (2013) conducted a study involving 100 patients including 
both primigravidae and multrigravidae to compare the efficacy of intravenous 
drotaverine hydrochloride and valethamate bromide in cervical dilatation. They 
found intravenous drotaverine hydrochloride is better than valethamate in 
acceleration of labour. 19 
 
Jayashree et al (2013) conducted a study involving 200 women to compare the 
efficacy of intramuscular drotaverine hydrochloride and valethamate bromide in 
first stage of labour. They found intramuscular drotaverine hydrochloride to be 
more effective than valethamate. 20 
 
Ibrahim MI et al (2014) in a randomized, double-blind, placebo-controlled trial 
conducted among 422 young nulliparous women to re-evaluate the role of 
 48 
 
drotaverine in progression of labour concluded that it can be used effectively and 
safely to shorten the duration of the first stage of labour among nulliparous 
women with active spontaneous labour.6 
 
Alka B Patil et al (2015) conducted a study involving 150 primigravidas to 
compare the efficacy of intramuscular drotaverine hydrochloride and valethamate 
bromide in progression of labour. They found intramuscular drotaverine 
hydrochloride is better and safe when compared to valethamate in shortening the 
duration of labour. 21 
 
K Srivastava et al (2015) conducted a comparative study among 60 women to 
study the effect of drotaverine hydrochloride with hyoscine butyl bromide in first 
stage of labour and concluded that both the drugs were effective in shortening the 
first stage of labour though there was no significant difference between the two 
drugs.22 
 
Aggarwal P et al (2008) conducted a prospective randomized control trial among 
104 primigravidae women to study the effect of intravenous hyoscine butyl 
bromide as labour analgesic and labour accelerant and concluded that it causes 
pain relief of up to 36% and is effective in shortening the active phase of first 
stage of labour without side effects.23 
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Nourah H al Qahtani et al (2011) conducted a randomized, double blind, 
controlled trial among 97 primigravidae women to study the effect of 
intramuscular hyoscine butyl bromide in reducing the duration of first stage of 
labour. They concluded that hyoscine butyl bromide is effective in significantly 
reducing first stage of labour without apparent adverse effects.24 
 
Fardiazar Z et al (2013) conducted a single blind, randomized, trial among 120 
primigravidae women to compare the effect of intravenous hyoscine butyl 
bromide verses atropine as labour accelerant and analgesic. It was concluded that 
hyoscine butyl bromide is preferable to atropine specially in reducing the length 
of first stage of pregnancy.25 
 
Faride M et al (2011) conducted a double blind, clinical trial among 140 pregnant 
women to study the effect of intravenous hyoscine butyl bromide upon delivery 
progression. It was concluded that hyoscine butyl bromide is effective in reducing 
the duration of first stage of pregnancy.26 
 
LA Samuels et al. (2007) conducted randomized, double-blinded, controlled trial 
among 129 women in active labour. They found that Hyoscine is effective in 
shortening the duration of labour and is not associated with adverse effects.27 
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Hussein Al-Khishaliet al. (2012) conducted a prospective, double blinded, 
controlled clinical trial among 200 primi- and multigravidae and found that 
Hyoscine significantly reduces the duration of active phase of labour  without any 
obvious maternal or fetal adverse effects.28 
 
Kirmani et al (2012) compared the efficacy of intravenous drotaverine to 
hyoscine butyl bromide rectal suppository among 300 pregnant women and found 
hyoscine butyl bromide to be more effective than drotaverine hydrochloride in 
shortening the first stage of labour .29 
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MATERIALS AND METHODS 
STUDY DESIGN: 
Prospective interventional comparative study 
 
STUDY AREA: 
The Government RSRM lying in hospital is a 500 bedded hospital dedicated to 
Obstetrics Gynaecology and Neonatology. It is a maternity and women’s health 
hospital attached to Stanley Medical College. On an average 10000 babies are 
delivered per year. 
 
STUDY POPULATION: 
Nulliparous women admitted in spontaneous active labour to the labour ward at 
Government Raja Sir Ramasamy Mudaliar Lying in Hospital, Stanley Medical 
College from March 2015 - August 2015. These women were selected according 
to Inclusion and Exclusion criteria. 
 
SAMPLE SIZE & SAMPLE TECNIQUE: 
A total of 600 nulliparous women were selected according to the Inclusion and 
Exclusion criteria. 
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INCLUSION CRITERIA: 
a) Primiparous Women 18-35 years of age 
b) Singleton term fetus ( gestational age between 37-41 weeks 6 days) 
c) Vertex Presentation 
d) Spontaneous onset of labour in active phase of labour (cervical 
dilatation of 3-4 cm) 
e) Intact membranes 
f) No contraindication for vaginal delivery 
g) No chronic or pregnancy induced illnesses 
h) Informed and written consent 
 
EXCLUSION CRITERIA: 
a) Women <18 and >35 years of age 
b) Multiparous 
c) Multiple gestation 
d) Cephalopelvic disproportion 
e) Malpresentation 
f) Induced labour 
g) Cervical dilatation of >4 cm 
h) Ruptured membranes 
i) Previous uterine scarring 
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j) Chronic or pregnancy induced illnesses 
k) Antepartum Haemorrhage 
l) Non reassuring fetal status 
m) Hypersensitivity to Drotaverine or Hyoscine 
 
A detailed history was taken and a thorough physical examination was done. A 
written informed consent was obtained from all the eligible participants. These 
600 women were randomly assigned into 3 groups namely A, B, C with each 
group having 200 women each. 
 
GROUP A - CONTROL GROUP: 
Women in this group belongs to control group. Hence progress of labour was 
monitored using a partogram. 
 
GROUP B - DROTAVERINE GROUP: 
These women received single dose of Inj. Drotaverine 40 mg intravenously at the 
onset of spontaneous active labour which is cervical dilatation of about 3-4 cm 
and the progress of labour was monitored using a partogram. 
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GROUP C - HYOSCINE GROUP: 
These women received single dose of Inj. Hyoscine 20 mg intravenously at the 
onset of spontaneous active labour which is cervical dilatation of about 3-4 cm 
and the progress of labour was monitored using a partogram. 
 
Artificial rupture of membranes was done under antibiotic cover. A partogram 
was maintained throughout the labour for every patient to monitor the progress 
of labour. Vaginal examination was done every 2hrs or earlier if required.  
Oxytocin infusion was started and titrated according to uterine contractions. 
 
Vitals monitoring and progress of labour was monitored which includes uterine 
contractions, progress and descent of presenting part, cervical dilatation and fetal 
heart sounds using a partogram. 
 
The 3 groups of patients were observed to record the primary and secondary 
outcomes. The observations that were noted are the time of onset of active labour 
(is the time at which the drug is given), time of full cervical dilatation, time of 
delivery of the baby and placenta. 
 
The primary outcome that are noticed are the duration of I, II, III Stage of labour 
and cervical dilation rate. Secondary outcome that are analysed are the mode of 
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delivery, maternal drug side effects, third stage complications and neonatal 
outcome (APGAR at 1 minute and 5 minutes, NICU admission). Both the primary 
and secondary outcomes were compared among groups. 
 
DATA ANALYSIS: 
All the data obtained was compiled and Statistical analysis of the data was done 
using SPSS version 18. The average time taken from time of injection of 
antispasmodic to full cervical dilatation (with baseline dilatation of 3 – 4 cm) will 
be measured. Statistical analysis is done by applying chi-square test for 
categorical data and ANOVA test to analyze the results observed among the three 
groups.   
.  
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RESULTS & ANALYSIS 
 This study was undertaken at Government RSRM Lying in hospital, 
Stanley Medical College, Chennai. 600 Nulliparous women were selected and 
divided in to three groups namely Group A or the Control Group, Group B or the 
Drotaverine Group and Group C or the Hyoscine Group. Each group was 
monitored as mentioned in the methodology of the dissertation and the 
observations were tabulated and analyzed. 
 
AGE DISTRIBUTION IN EACH GROUP 
Out of the 600 patients studied, about 543 women belonged to the age group of 
18 - 20 years and 21 - 25 years which was about 90.5% women as our study was 
done among nulliparous women. 
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Table 3. Age Distribution in each Group 
 
Age Group in years 
Group  
Total Control Drotaverine Hyoscine 
 
 
18-20 
Count 101 98 90 289 
% within Age Group in 
years 
34.9% 33.9% 31.1% 100.0% 
% within Group 50.5% 49.0% 45.0% 48.2% 
 
21-25 
Count 85 77 92 254 
% within Age Group in 
years 
33.5% 30.3% 36.2% 100.0% 
% within Group 42.5% 38.5% 46.0% 42.3% 
 
26-30 
Count 13 21 17 51 
% within Age Group in 
years 
25.5% 41.2% 33.3% 100.0% 
% within Group 6.5% 10.5% 8.5% 8.5% 
 
31-35 
Count 1 4 1 6 
% within Age Group in 
years 
16.7% 66.7% 16.7% 100.0% 
% within Group .5% 2.0% .5% 1.0% 
 
Total 
Count 200 200 200 600 
% within Age Group in 
years 
33.3% 33.3% 33.3% 100.0% 
% within Group 100.0% 100.0% 100.0% 100.0% 
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                                         Chart 1: Age Distribution in each Group 
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GRAVIDITY DISTRIBUTION IN EACH GROUP 
Table 4: Gravidity Distribution in each Group 
 
Obstetric  Code 
 
Group  
Total Control Drotaverine Hyoscine 
 
 
Primi 
Count 186 189 183 558 
% within Obs Code 33.3% 33.9% 32.8% 100.0% 
% within Group 93.0% 94.5% 91.5% 93.0% 
 
G2A1 
Count 13 8 16 37 
% within Obs Code 35.1% 21.6% 43.2% 100.0% 
% within Group 6.5% 4.0% 8.0% 6.2% 
 
G3A2 
Count 1 3 1 5 
% within Obs Code 20.0% 60.0% 20.0% 100.0% 
% within Group .5% 1.5% .5% .8% 
 
Total 
Count 200 200 200 600 
% within Obs Code 33.3% 33.3% 33.3% 100.0% 
% within Group 100.0% 100.0% 100.0% 100.0% 
 
 
 
 
Among all the three groups, majority of the patients were primigravidas which 
was about 558 women constituting about 93% of the total study group. The 
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remaining 6.2% was second gravida and only 0.8% of the study group constituted 
third gravida. 
 
              
 
 
 
   
                                 Chart 2: Gravidity Distribution in each Group 
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OXYTOCIN AUGMENTATION 
 
Table 5: Oxytocin Augmentation 
 
 
Oxytocin 
 
Group  
Total Control Drotaverine Hyoscine 
 
 
Yes 
Count 121 103 95 319 
% within Oxytocin 37.9% 32.3% 29.8% 100.0% 
% within Group 60.5% 51.5% 47.5% 53.2% 
 
No 
Count 79 97 105 281 
% within Oxytocin 28.1% 34.5% 37.4% 100.0% 
% within Group 39.5% 48.5% 52.5% 46.8% 
 
Total 
Count 200 200 200 600 
% within Oxytocin 33.3% 33.3% 33.3% 100.0% 
% within Group 100.0% 100.0% 100.0% 100.0% 
 
60.5%, 51.5%, and 47.5% from control, drotaverine and hyoscine group required 
oxytocin infusion drip to establish active uterine contractions. This was about 319 
patients of the total study groups constituting 53.2%. 
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                                              Chart 3: Oxytocin Augmentation 
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DURATION OF ACTIVE PHASE OF LABOUR 
 
Table 6: Duration of active phase of labour (min) 
 
Group N Mean Std. Deviation 
 
P  value 
Control 184 213.51 25.874 .000 
Drotaverine 180 162.58 19.828 
Hyoscine 181 148.57 31.033 
Total 545 175.12 38.186 
 
In the control group the mean duration of active labour was 213.51 minutes. In 
the Drotaverine group it was found to be 162.58 minutes. In the Hyoscine group 
the mean duration of active labour was found to be 148.57 minutes.  
               Table 7: Duration of active phase of labour (min) – Multiple Comparisons 
 
(I) Group (J) Group Mean Difference (I-J) Std. Error Sig. 
Control Drotaverine 50.92(*) 2.725 
.000 
Hyoscine 64.94(*) 2.721 
Drotaveri
ne 
Control -50.92(*) 2.725 
Hyoscine 14.01(*) 2.736 
Hyoscine Control -64.94(*) 2.721 
Drotaverine -14.01(*) 2.736 
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The difference among all the three groups within one another was found to be 
significant. The mean duration of active stage of labour was significantly lower 
than the control group when compared to the Drotaverine and the hyoscine group. 
When compared to Drotaverine the hyoscine group had statistically significant 
difference in the mean duration of active stage of labor. 
        
 
Chart 4: Duration of active phase of labour (min) 
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CERVICAL DILATATION RATE 
Table 8: Cervical dilatation Rate. 
Group N Mean 
Std. 
Deviation Std. Error Sig. 
Control 184 1.7090 .19099 .01408 
.000 
Drotaverine 180 2.2427 .23811 .01775 
Hyoscine 181 2.5146 .45396 .03374 
Total 545 2.1528 .46038 .01972 
In the control group the rate of cervical dilatation was 1.7090 cm/hr. In the 
Drotaverine group it was found to be 2.2427 cm/hr. In the Hyoscine group the 
rate of cervical dilatation was found to be 2.5146 cm/hr. This was found to be 
statistically significant. 
 Table 9: Cervical dilatation Rate – Multiple comparisons 
(I) Group (J) Group 
Mean Difference 
(I-J) Std. Error Sig. 
Control Drotaverine -.5337(*) .03307 
.000 
 
Hyoscine -.8056(*) .03302 
Drotaverine Control .5337(*) .03307 
 Hyoscine -.2719(*) .03320 
Hyoscine Control .8056(*) .03302 
 Drotaverine .2719(*) .03320 
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 The difference among the three groups were statistically significant among one 
another as its evident from the table given above. 
 
 
 
 
 
 
 
Chart 5: Cervical dilatation Rate. 
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DURATION OF II STAGE OF LABOUR 
 
Table 10: Duration of II stage of labour (min) 
 
 
Group N Mean Std. Deviation Std. Error 
Control 184 50.19 8.547 .630 
Drotaverine 180 48.61 7.858 .586 
Hyoscine 181 49.60 8.241 .613 
Total 545 49.47 8.233 .353 
 
 
There was no significant difference in the duration of second stage of labour 
among all the three groups. Hence this shows that these drugs have no role in 
second stage of labour. 
                                
 
            Chart 6: Duration of II stage of labour (min) 
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  DURATION OF III STAGE OF LABOUR 
 
Table 11: Duration of III stage of labour (min) 
 
Group N Mean Std. Deviation Std. Error 
Control 184 9.09 .734 .054 
Drotaverine 181 9.09 .705 .052 
Hyoscine 181 9.06 .776 .058 
Total 546 9.08 .738 .032 
 
There was no significant difference in the duration of third stage of labour among 
all the three groups. 
 
                                               Chart 7: Duration of III stage of labour(min) 
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MODE OF DELIVERY 
Table 12: Mode of delivery 
 
 
Mode of delivery 
 
Group  
Total Control Drotaverine Hyoscine 
 
 
VD 
Count 174 166 172 512 
% within Mode 
of delivery 
34.0% 32.4% 33.6% 100.0
% 
% within Group 87.0% 83.0% 86.0% 85.3% 
 
OVD 
Count 10 14 9 33 
% within Mode 
of delivery 
30.3% 42.4% 27.3% 100.0
% 
% within Group 5.0% 7.0% 4.5% 5.5% 
 
LSCS 
Count 16 20 19 55 
% within Mode 
of delivery 
29.1% 36.4% 34.5% 100.0
% 
% within Group 8.0% 10.0% 9.5% 9.2% 
 
Total 
Count 200 200 200 600 
% within Mode 
of delivery 
33.3% 33.3% 33.3% 100.0
% 
% within Group 100.0% 100.0% 100.0% 100.0
% 
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Majority of the women in all the groups had vaginal deliveries. It constituted 
about 85.3% of the entire 600 patients. There was no significant difference in the 
incidence of vaginal deliveries. 
Operative vaginal deliveries constituted 5.5% of the total number of deliveries. 
The difference in their incidence in all the three groups were found to be 
insignificant, the indication for them being either maternal exhaustion or fetal 
distress. 
LSCS constituted 9.2% of the total deliveries. The indication for LSCS was either 
fetal distress or Failure to progress 
 
 
 
Chart 8: Mode of delivery in all groups 
 
 
 71 
 
 
 
 
 
 
Chart 9: Mode of delivery – Control Group 
 
 
 
 
 
Chart 10: Mode of delivery – Drotaverine Group 
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Chart 11: Mode of delivery – Hyoscine group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
 
APGAR SCORE AT 1 MINUTE 
 
Table 13: Apgar 1 minute 
 
 
Apgar 1 min 
Group  
Total Control Drotaverine Hyoscine 
 
 
5 
Count 7 8 7 22 
% within Apgar 1 min 31.8% 36.4% 31.8% 100.0% 
% within group 3.5% 4.0% 3.5% 3.7% 
 
6 
Count 106 108 107 321 
% within Apgar 1 min 33.0% 33.6% 33.3% 100.0% 
% within group 53.0% 54.0% 53.5% 53.5% 
 
7 
Count 87 84 86 257 
% within Apgar 1 min 33.9% 32.7% 33.5% 100.0% 
% within group 43.5% 42.0% 43.0% 42.8% 
 
Total 
Count 200 200 200 600 
% within Apgar 1 min 33.3% 33.3% 33.3% 100.0% 
% within group 100.0% 100.0% 100.0% 100.0% 
 
Only 3.7% of the total number of babies delivered had Apgar score as 5. The 
remaining 96.3% of the babies had Apgar of 6 or 7. 
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APGAR SCORE AT 5 MINUTE 
 
Table 14: Apgar 5 minute 
 
 
Apgar 5 min 
Group  
Total Control Drotaverine Hyoscine 
 
 
7 
Count 0 2 0 2 
% within Apgar 5 min .0% 100.0% .0% 100.0% 
% within group .0% 1.0% .0% .3% 
 
8 
Count 112 90 133 335 
% within Apgar 5 min 33.4% 26.9% 39.7% 100.0% 
% within group 56.0% 45.0% 66.5% 55.8% 
 
9 
Count 88 108 67 263 
% within Apgar 5 min 33.5% 41.1% 25.5% 100.0% 
% within group 44.0% 54.0% 33.5% 43.8% 
 
Total 
Count 200 200 200 600 
% within Apgar 5 min 33.3% 33.3% 33.3% 100.0% 
% within group 100.0% 100.0% 100.0% 100.0% 
 
Only 0.3% of the total number of babies delivered had Apgar score as 7. The  
remaining 99.7% of the babies had Apgar as 8 or 9. The 1 min and 5 min Apgar 
score showed no statistically significant difference among all the three groups 
hence confirming that the drugs have no adverse perinatal outcome and confirms 
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the safety of using these drugs in labour. 
                                    
                              Chart 12: Apgar 1 minute 
    
                                            
                                                                  Chart 13: Apgar 5 minute 
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BIRTH WEIGHT 
 
Table 15: Birth weight 
 
 
Birth weight in kg 
Group  
Total Control Drotaverine Hyoscine 
 
 
2.0 – 2.5 
Count 42 41 31 114 
% within weight  36.8% 36.0% 27.2% 100.0% 
% within group 21.0% 20.5% 15.5% 19.0% 
 
2.5 – 3.0 
Count 115 111 118 344 
% within weight  33.4% 32.3% 34.3% 100.0% 
% within group 57.5% 55.5% 59.0% 57.3% 
 
>3.0 
Count 43 48 51 142 
% within weight  30.3% 33.8% 35.9% 100.0% 
% within group 21.5% 24.0% 25.5% 23.7% 
 
Total 
Count 200 200 200 600 
% within weight  33.3% 33.3% 33.3% 100.0% 
% within group 100.0% 100.0% 100.0% 100.0% 
 
About 19% of the babies were less than 2.5 kg in weight and the remaining were 
more than 2.5 kg. 
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Chart 14: Birth weight 
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NICU ADMISSION 
 
Table 16: NICU admission 
 
 
NICU admission 
Group  
Total Control Drotaverine Hyoscine 
 
 
Yes 
Count 2 2 2 6 
% within NICU 
Admission 
33.3% 33.3% 33.3% 100.0% 
% within Group 1.0% 1.0% 1.0% 1.0% 
 
No 
Count 198 198 198 594 
% within NICU 
Admission 
33.3% 33.3% 33.3% 100.0% 
% within Group 99.0% 99.0% 99.0% 99.0% 
 
 
Only 1% of the babies were admitted in NICU. This further confirms the safety 
of using these drugs in labour. 
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Chart 15: NICU admission 
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THIRD STAGE COMPLICATIONS 
 
Table 17: Third stage Complications 
 
 
          Complications 
Group  
Total Control Drotaverine Hyoscine 
 
Nil Count 195 192 193 580 
% within group 97.5% 96.0% 96.5% 96.7% 
Postpartum 
hemorrhage 
Count 2 4 4 10 
% within group 1.0% 2.0% 2.0% 1.7% 
Vaginal 
Laceration 
Count 3 4 3 10 
% within group 1.5% 2.0% 1.5% 1.7% 
 
Third stage complications were almost similar in all the three groups. Postpartum 
hemorrhage was seen in 1.7% and vaginal laceration was seen in 1.7% of the total 
deliveries. 
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MATERNAL ADVERSE EFFECTS 
Table 18: Maternal Adverse Effects 
 
Maternal Adverse effects 
Group 
Drotaverine Hyoscine 
 
Nil 188 190 
Maternal tachycardia 4 4 
Nausea 2 1 
Headache 1 1 
Vomiting 5 3 
Photophobia 0 1 
 
Of the total study population 8 patients had tachycardia, 3 had nausea, 8 had 
vomiting, 2 had headache and 1 patient had photophobia. 6% of the Drotaverine 
group and 5% of the hyoscine group exhibited adverse effects which was found 
to be statistically insignificant when compared to the control group. 
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 DISCUSSION 
Active management of labour is meant to shorten the duration of the labour. More 
than 30 years ago, O'Driscoll and colleagues (1984) at the National Maternity 
Hospital in Dublin pioneered the concept that a disciplined, standardized labor 
management protocol reduced the number of cesarean deliveries for dystocia. 
Their overall cesarean delivery rate was 5 percent in the 1970s and 1980s with 
such management. The approach is now referred to as active management of 
labour.2  
 
This helps to avoid prolonged labour which every obstetrician considers it to be 
a dreaded complication. Prolonged labour can be avoided by facilitating cervical 
dilatation as cervical spasm is the most common cause of prolonged labour.20 
 
Prolonged labour leads to maternal complications like risk of caesarean section, 
endometritis, postpartum hemorrhage and fetal complications like fetal distress 
and fetal and infant mortality rate increases.26 
 
Hirsch was the first one who described the use of antispasmolytic drugs to shorten 
the duration of the first stage of labour in 1937: he reported that duration of labour 
can be reduced by 2–4 hours by using an atropine-like drug. Antispasmodic drugs 
are used to facilitate cervical dilatation during labour via neurotropic and/or 
musculotropic effects.11 
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Drotaverine hydrochloride and Hyoscine butyl bromide are widely used now a 
days for facilitation of cervical dilatation thereby shortening the duration of active 
phase of labour resulting in augmentation of labour. Various trials as quoted 
below have been done in proving the safety and efficacy of both drotaverine and 
hyoscine. 
 
The present study inferred that both Drotaverine hydrochloride and Hyoscine 
butyl bromide caused a significant reduction in the active phase of labour when 
compared to the control group. This confirms the efficacy of these two drugs in 
its usage in augmentation of labour among nulliparous women as suggested by 
various studies done before. 
 
Sharma et al (2001) in his study of drotaverine hydrochloride versus valethamate 
bromide in acceleration of labour found both intramuscular drotaverine 
hydrochloride and valethamate bromide are effective in shortening the duration 
of labour; however, drotaverine augments labour more rapidly and is associated 
with less side effects. The mean injection delivery interval is 220 minutes in 
valethamate group and 193 minutes in drotaverine group and 412 minutes in 
control group which was statistically significant (P < 0.05).  15 
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Singh et al (2004) in his study of drotaverine hydrochloride in augmentation of 
labour found intramuscular drotaverine hydrochloride to be safe and effective in 
augmentation of labour. There was 15% reduction of duration of first stage of 
labour when compared to the control group 16 
 
Tripti et al (2009) in his study to compare and evaluate the efficacy and safety of 
drotaverine hydrochloride and valethamate bromide concluded drotaverine 
hydrochloride is safe and more effective than intravenous infusion of valethamate 
in shortening the duration of labour. The mean duration of active phase of labour 
in 177 minutes in valethamate group and 113 minutes in drotaverine group which 
was statistically significant (P < 0.05).   17 
 
Madhu et al (2010) conducted a   prospective randomized study among 146 low 
risk women in spontaneous labour to compare the efficacy of intramuscular 
drotaverine hydrochloride and valethamate bromide in augmentation of labour. 
They found intramuscular drotaverine hydrochloride to be superior to 
valethamate with fewer side effects in augmentation of first stage of labour. The 
mean injection delivery interval is 206 minutes in valethamate group and 183 
minutes in drotaverine group and 245 minutes in control group which was 
statistically significant (P < 0.05). 18 
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Sudhir Babu Palii et al (2013) concluded in his comparative study of drotaverine 
hydrochloride and valethamate bromide in first stage of labour that intravenous 
drotaverine hydrochloride is better than valethamate in acceleration of labour. . 
The mean duration of active phase of labour is 254  minutes in valethamate group 
and 186 minutes in drotaverine group which was statistically significant (P < 
0.05) 19 
 
Jayashree et al (2013) in her study of comparison of drotaverine hydrochloride 
and valethamate bromide in first stage of labour found intramuscular drotaverine 
hydrochloride to be more effective than valethamate. . The mean duration of 
active phase of labour was 160 minutes in valethamate group and 123 minutes in 
drotaverine group which was statistically significant (P < 0.001).20 
 
Ibrahim MI et al (2014) in his study of drotaverine to improve progression of 
labour among nulliparous women concluded that it can be used effectively and 
safely to shorten the duration of the first stage of labour. The mean duration of 
active phase of labour was 200 minutes in control group, 120 minutes in 
drotaverine group which was statistically significant (P < 0.001)..6 
 
Alka B Patil et al (2015) in her comparative study drotaverine hydrochloride and 
valethamate bromide in progress of labour found intramuscular drotaverine 
hydrochloride is better and safe when compared to valethamate in shortening the 
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duration of labour. The mean duration of active phase of labour was 305 minutes 
in control group, 158 minutes in valethamate group and 113 minutes in 
drotaverine group which was statistically significant (P < 0.001).  21 
 
K Srivastava et al (2015) in his comparative study of the effect of drotaverine 
hydrochloride with hyoscine butyl bromide in first stage of labour and concluded 
that both the drugs were effective in shortening the first stage of labour though 
there was no significant difference between the two drugs. A significant 
difference among group was observed in first stage and total duration of labor 
(p<0.001) 22 
  
Aggarwal P et al (2008) in his study of role of hyoscine butyl bromide as labour 
accelerant concluded that it causes pain relief of up to 36% and is effective in 
shortening the active phase of first stage of labour without side effects.23 
 
Nourah H al Qahtani et al (2011) in his study of the effect of hyoscine 
butylbromide in shortening the first stage of labour concluded that intramuscular 
hyoscine butyl bromide significantly reduced first stage of labour without 
apparent adverse effects. The mean duration of active phase of labour was 165 
minutes in hyoscine group verses 215 minutes in control group which was 
statistically significant (P < 0.001). 24 
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Fardiazar Z et al (2013) in his study of Hyoscine verses atropine as labour 
accelerant and analgesic concluded that hyoscine butyl bromide is preferable to 
atropine specially in reducing the length of first stage of pregnancy. The mean 
length of active phase of labour was 218.5 in hyoscine verses 339 minutes in 
atropine group which was statistically significant (P < 0.05). 25 
 
Faride M et al (2011) in his study of effects of hyoscine on the first stage of labour 
in full term pregnancies concluded that intravenous hyoscine butyl bromide is 
effective in reducing the duration of first stage of pregnancy. The mean time for 
the active phase of labour was 113.5 minutes compared to 100.64 minutes in drug 
group which was statistically significant ( P = 0.045). 26 
 
LA Samuels et al. (2007) in his study of the effect of hyoscine butyl bromide on 
the first stage of labour in term pregnancies concluded that Hyoscine is effective 
in significantly shortening duration of labour and is not associated with adverse 
effects either in mother or in the fetus. The mean duration of active stage of labour 
was 228 minutes among the control group while it was only 156 minutes in the 
drug group showing a decrease of 31.7% (P = 0.001) hence statistically 
significant. 27 
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Hussein Al-Khishaliet al. (2012) concluded in his study of  the effect of 20 mg 
Hyoscine Butyl bromide on Normal Labor in Iraqi Primi- and Multi-gravida 
Women that Hyoscine significantly reduces the duration of active phase of labour  
without any obvious maternal or fetal adverse effects. . The mean duration of 
active stage of labour was 193.8 minutes among the control group while only 
167.7 minutes in the drug group. Hence it is statistically significant.27 
 
Kirmani et al (2012) in his study of efficacy of Drotaverine in Comparison to 
Hyoscine Butyl bromide in Augmentation of Labour found hyoscine butyl 
bromide to be more effective than drotaverine hydrochloride in shortening the 
first stage of labour. The mean duration of first stage of labour was 179.1 min, 
159.3 min and 299 min in drotaverine, hyoscine and control group respectively 
which was statistically significant.29 
 
The results of the present study were compared with other studies and analysed. 
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COMPARISON OF MEAN AGE IN VARIOUS STUDIES 
Table 19: Comparison of Mean Age 
 
S No 
 
Name of Study 
Group (Age in years) 
Control Drotaverine Hyoscine 
1.  Tripti et al (2009)  22.76+2.71  
2.  Ibrahim MI et al (2014) 23.8+3.4 23.8+3.8  
3.  Alka B Patil et al (2015) 25.8+2.99 24.26+3.78  
4.  Nourah H al Qahtani et al (2011) 24.4  23.9 
5.  Faride M et al (2011) 23.9±6  24.4±5.7 
6.  LA Samuels et al. (2007) 26.9+6.2  25.0+6.0 
7.  Hussein Al-Khishaliet al. (2012) 25.7±5.5  25.9±5.2 
8.  Kirmani et al (2012) 25+3.3 24.9+3.2 24.8+3 
9.  Present Study 21 21.5 21.4 
 
In the present study the mean age in the control group was of 21 years while it is 
21.5 and 21.4 years in Drotaverine and Hyoscine group respectively.  In the study 
conducted by Kirmani et al the mean age in the control group was of 25+3.3 years 
while it is 24.9+3.2 and 24.8+3 years in the drotaverine and Hyoscine group 
respectively. 
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COMPARISON OF DURATION OF ACTIVE PHASE OF LABOUR IN 
VARIOUS STUDIES 
Table 20: Comparison of Duration of Active phase of Labour 
 
S No 
 
Name of Study 
Group (duration in minutes) 
Control Drotaverine Hyoscine 
1.  Sharma et al (2001) 412 193  
2.  Tripti et al (2009)  113  
3.  Madhu et al (2010) 245 183  
4.  Sudhir Babu Palii et al (2013)  186  
5.  Jayashree et al (2013)  123  
6.  Ibrahim MI et al (2014) 200 120  
7.  Alka B Patil et al (2015) 305 113  
8.  Nourah H al Qahtani et al (2011) 215  165 
9.  Fardiazar Z et al (2013)   218.5 
10. Faride M et al (2011) 113.5  100.64 
11. LA Samuels et al. (2007) 228  156 
12. Hussein Al-Khishaliet al. (2012) 193.8  167.7 
13. Kirmani et al (2012)  299 179 159 
14. Srivastava et al (2015) 345 224 230 
15. Present Study 213.51 162.58 148.57 
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In the present study the duration of active phase of labour was 213.51 minutes in 
control group while in drotaverine and hyoscine groups were 162.58 minutes and 
148.57 minutes respectively. There was significant reduction in the duration of 
active phase of labour when compared among one another in all three groups 
which was statistically significant.  
 
Though not the same duration of labour similarly statistically significant 
difference in the duration of active phase of labour was noticed in studies 
conducted by Kirmani et al and Srivastava et al among the three groups. 
 
In the study conducted by Kirmani et al the duration of active phase of labour was 
299 minutes in control group while in drotaverine and hyoscine groups were 179 
minutes and 159 minutes respectively. 
 
In the study conducted by Srivastava et al the duration of active phase of labour 
was 345 minutes in control group while in drotaverine and hyoscine groups were 
224 minutes and 230 minutes respectively. 
 
Various other studies have also been quoted in the tabular column which clearly 
confirms the efficacy of these two drugs in reducing the duration of active phase 
of labour. 
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COMPARISON OF CERVICAL DILATATION RATE IN VARIOUS 
STUDIES 
Table 21: Comparison of Cervical dilatation Rate  
 
S No 
 
Name of Study 
Group (rate in cm/hr) 
Control Drotaverine Hyoscine 
1.  Tripti et al (2009)  2.89  
2.  Madhu et al (2010) 1.9 3  
3.  Sudhir Babu Palii et al (2013)  1.92  
4.  Jayashree et al (2013)  3.31  
5.  Ibrahim MI et al (2014) 1.8 2.7  
6.  Alka B Patil et al (2015) 1.5 2.6  
7.  LA Samuels et al. (2007)   2.6 
8.  Kirmani et al (2012) 2 2.6 2.9 
9.  Present Study 1.7 2.2 2.5 
 
 
In the present study the cervical dilatation rate was 1.7 cm/hr in control group 
while in drotaverine and hyoscine groups was 2.2 cm/hr and 2.5 cm/hr 
respectively. There was significant reduction in the cervical dilatation rate when 
compared with the control group which was statistically significant.  
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In the study conducted by Kirmani et al the cervical dilatation rate was 2 cm/hr 
in control group while in drotaverine and hyoscine groups were 2.6 cm/hr and 2.9 
cm/hr respectively. 
 
In the study conducted by LA Samuels et al the cervical dilatation rate was 2.6 
cm/hr in hyoscine group which was similar to the present study. 
 
The cervical dilatation rate in drotaverine group was though not comparable with 
previous studies but was statistically significant in comparison to the control 
group confirming the efficacy of the drug in augmentation of labour. 
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COMPARISON OF DURATION OF SECOND STAGE OF LABOUR 
Table 22: Comparison of Duration of second stage of Labour 
 
S No 
 
Name of Study 
Group (duration in minutes) 
Control Drotaverine Hyoscine 
1.  Tripti et al (2009)  21  
2.  Ibrahim MI et al (2014) 42.2 38  
3.  Alka B Patil et al (2015) 30.9 22.8  
4.  Nourah H al Qahtani et al (2011) 40  28 
5.  Faride M et al (2011) 26.5  25.2 
6.  LA Samuels et al. (2007) 20  15 
7.  Hussein Al-Khishaliet al. (2012) 22.6  23.4 
8.  Kirmani et al (2012) 26.8 25.9 24.9 
9.  Srivastava et al (2015) 36.11 27.25 24 
10. Present Study 50.19 48.61 49.60 
 
The duration of second stage of labour was 50.19 minutes in control group, 
48.61 minutes in Drotaverine group and 49.60 minutes in Hyoscine group in the 
present study. The duration of second stage of labour among all the three groups 
was found to be statistically insignificant. 
Various studies quoted above confirms that the usage of these spasmolytic 
drugs have no role in the duration of second stage of labour. 
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COMPARISON OF DURATION OF THIRD STAGE OF LABOUR 
Table 23: Comparison of Duration of third stage of Labour 
 
S No 
 
Name of Study 
Group (duration in minutes) 
Control Drotaverine Hyoscine 
1.  Tripti et al (2009)  4.62  
2.  Ibrahim MI et al (2014) 9.1 8.9  
3.  Alka B Patil et al (2015) 8.1 8.1  
4.  Faride M et al (2011) 7.1  6.9 
5.  LA Samuels et al. (2007) 8  10 
6.  Hussein Al-Khishaliet al. (2012) 9.7  11.7 
7.  Kirmani et al (2012) 6.7 7.1 7 
8.  Srivastava K et al (2015) 7.78 6.25 6.6 
9.  Present Study 9.09 9.09 906 
The duration of third stage of labour was 9.09 minutes in control group, 9.09 
minutes in Drotaverine group and 9.06 minutes in Hyoscine group in the present 
study. The duration of third stage of labour among all the three groups was 
found to be statistically insignificant. 
Third stage complications were almost similar in all the three groups. PPH was 
found in 1%, 2%, and 2% of the women in Control, Drotaverine and Hyoscine 
group respectively. Vaginal laceration was found in 1.5%, 2%, and 1.5% of the 
women in Control, Drotaverine and Hyoscine groups respectively. 
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COMPARISON OF MODE OF DELIVERY IN VARIOUS STUDIES 
Table 24: Comparison of Mode of delivery  
Mode  of 
delivery 
Drug Given Present study Kirmani et al 
(2012) 
Srivastava et al 
(2015) 
Vaginal Drotaverine 86% 92% 85% 
Hyoscine 83% 92% 95% 
Control 87% 90% 70% 
Operative 
Vaginal 
Drotaverine 7% 4.7% 0% 
Hyoscine 4.5% 4% 5% 
Control 5% 4.7% 0% 
LSCS Drotaverine 10% 3.3% 10% 
Hyoscine 9.5% 4% 5% 
Control 8% 5.3% 30% 
 
In the present study there was no significant difference in the mode of delivery 
among the three groups. The percentage of vaginal delivery was almost similar 
in all the three groups. Similarly the percentage of LSCS was also found to be 
comparable. Operative vaginal delivery was bit higher in the drotaverine group 
when compared to the control group and hyoscine group but was not statistically 
significant 
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Table 25: Mode of Delivery in Drotaverine Group  
 
Name of Study 
Drotaverine Group 
Vaginal Operative vaginal LSCS 
Tripti et al (2009) 93% 6% 1% 
Ibrahim MI et al (2014) 90.1% 3.7% 6.2% 
Present Study 86% 7% 10% 
When compared to the various other studies the present study has higher rate of 
caesarean section but operative vaginal delivery is comparable to the study 
conducted by Tripti et al (2009) 
Table 26: Mode of Delivery in Hyoscine Group  
 
Name of Study 
Hyoscine Group 
Vaginal Operative vaginal LSCS 
Nourah H al Qahtani et al (2011) 78% 13% 9% 
LA Samuels et al. (2007) 93.3% 6.7% 
Present Study 83% 4.5% 9.5% 
The rate of Caesarean section in the present study is similar to the study conducted 
by LA Samuels et al (2007) and Nourah H al Qahtani et al (2011). The rate of 
vaginal delivery is also comparable to the above mentioned studies. 
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ADVERSE EFFECTS IN DROTAVERINE GROUP 
Table 27: Adverse effects in Drotaverine Group  
Study Maternal 
tachycardia 
Nausea & 
vomitting 
Headache 
Tripti et al (2009) 3% 4% - 
Ibrahim MI et al (2014) 4.3% 3.7% 3.7% 
Alka B Patil et al (2015) 12% 0% 6% 
Jayashree et al (2013) 3.45% 1.15% - 
Kirmani et al (2012) 1.3% 0.7% - 
Present Study 2% 3.5% 0.5% 
 
 There was no significant difference in maternal adverse effects among the three 
groups. Maternal tachycardia was noticed in 2% of the women, nausea & 
vomiting in 3.5% and headache in 0.5% of the women.  
 
The percentage of nausea & vomiting was comparable to the study conducted by 
Ibrahim MI et al (2014).  
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ADVERSE EFFECTS IN HYOSCINE GROUP  
Table 28. Adverse effects in Hyoscine Group  
Study Maternal 
tachycardia 
Nausea & 
vomitting 
Headache Photophobia 
Kirmani et al (2012) 0.7% 1.3% - - 
Present Study 2% 2.0% 0.5% 0.5% 
 
Maternal tachycardia was noticed in 2% of the women, nausea & vomiting in 2% 
headache and photophobia in 0.5% each of the women in the Hyoscine group 
 
Though headache and photophobia was not reported in study conducted by 
Kirmani et al (2012) it has been reported in the present study. 
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SUMMARY 
This prospective interventional comparative study was done among 600 
nulliparous women to compare the efficacy of intravenous Drotaverine 
hydrochloride and Hyoscine butyl bromide in augmentation of labour. 
 
For these nulliparous women who were in active labour with 3-4cm cervical 
dilatation, artificial rupture of membranes was done and were randomly divided 
into three groups. Oxytocin infusion was initiated if the initial progress of labour 
was unsatisfactory 
 
Drotaverine group when compared to control group showed a reduction in the 
duration of active phase by 50.92 minutes among nulliparous women which is 
statistically significant. 
 
Hyoscine group when compared to control group showed a reduction in the 
duration of active phase by 64.94 minutes among nulliparous women which is 
statistically significant. 
 
Drotaverine group when compared to Hyoscine showed a reduction in the 
duration of active phase by 14 minutes among nulliparous women which is 
statistically significant. 
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The cervical dilatation rate was 1.70 cm/hr, 2.24 cm/hr, 2.51 cm/hr in control 
group, drotaverine group, and hyoscine group respectively which was statistically 
significant. 
 
There was no significant change in the duration of II stage of labour among all 
the three groups. 
 
In Control group 87% of women had spontaneous vaginal delivery, 5% of women 
had forceps delivery and 8% of women had caesarean section. In Drotaverine 
group 83 % of women had spontaneous vaginal delivery, 7% of women had 
forceps delivery and 10% of women had caesarean section. In Hyoscine group 
86 % of women had spontaneous vaginal delivery, 4.5% of women had forceps 
delivery and 9.5% of women had caesarean section. Drotaverine and Hyoscine 
did not influence the mode of delivery. 
 
There was no significant change in the duration of III stage of labour and maternal 
complications among all the three groups. 
 
The side effects observed in both the groups were insignificant. 
 
There was no difference in perinatal outcome among the groups. 
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CONCLUSION 
1. Both Drotaverine hydrochloride and Hyoscine Butyl bromide is effective in 
shortening the duration of first stage of labour by virtue of faster cervical 
dilatation there by helping in augmentation of labour among the nulliparous 
women. 
2. Hyoscine butyl bromide is a superior cervical dilatation agent as compared to 
Drotaverine hydrochloride.  
3. Of the two drugs Hyoscine butyl bromide seems to be more effective than 
Drotaverine hydrochloride in augmentation of labour among the nulliparous 
women. 
4. Both Drotaverine and Hyoscine didn't affect the duration of second and third 
stage of labour. 
5. Both the drugs didn't show any major increase in operative vaginal delivery or 
cesarean section rate. 
6. Both the drugs didn't show any increase in third stage complications. 
7. Both the drugs had no significant maternal or fetal adverse effects 
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SUGGESTION 
Further studies have to be done to emphasize the efficacy of both Drotaverine and 
Hyoscine usage in shortening the duration of labour and promoting safe delivery 
with no maternal or fetal adverse effects so that these drugs can be included in 
the active management of labour. 
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PROFORMA 
Name   :     Age       : 
Occupation  :             Socioeconomic Status: 
DOA   :     IP No       : 
Husband’s Name :     Blood group                : 
Booking Status :     Immunization      : 
Gravida:     Para:      Live:    Abortion:          LMP:        EDD: 
H/O     month’s amenorrhea 
C/O     Lower abdominal pain 
         Discharge per vaginum 
  Able to perceive fetal movements  
H/O Present pregnancy: 
I trimester  : 
II trimester  : 
   III trimester  : 
Menstrual History  : Menarche 
     Regular / irregular 
     LMP 
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Marital History   : Married since 
    Consanguinity 
Obstetric History  : 
Past History   :Diabetic/Hypertensive/Tuberculosis/Epilepsy/Heart
     disease/ Thyroid disorder/Bronchial asthma 
Personal History  : 
 
Family History  : 
 
General examination: 
Built:    Nourishment:    Height:           Weight:  BMI: 
Pallor/ Icterus/ Cyanosis/ Clubbing/ Pedal edema/ Lymphadenopathy 
Breast:     Thyroid:            Spine:            Gait:  
Systemic examination : 
Cardiovascular system : 
Respiratory system : 
Abdominal examination : 
Per vaginal examination :  
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Non stress test    : 
Ultrasound     : 
ARM Done at    : 
Partogram     : 
Parameters studied    : 
Group Time at 4 
cm cervical 
dilatation 
Time at full 
dilatation 
Time of 
delivery of 
baby 
Time of 
delivery of 
placenta 
A:Control     
B:Drotaverine     
C:Hyoscine     
Mode of delivery  : Spontaneous vaginal/ Forceps delivery 
          /LSCS (Indication) 
Complications  : Tears / Atonic PPH      
Drug side effects  : vomitting/dryness of mouth/ tachycardia/headache 
Neonatal outcome  : Birth weight 
  APGAR  
  NICU admission 
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ABBREVIATION 
 
1. ANP - Atrial natriuretic peptide  
2. BNP - Brain natriuretic peptide 
3. cAMP - Cyclic adenosine monophosphate 
4. cGMP - Cyclic guanosine monophosphate 
4. COX-1- Cyclooxygenase-1 
5. COX- 2- Cyclooxygenase-2 
5. GAG – Glycosaminoglycan 
6. PAF - Platelet-activating factor 
7. PGD2 –Prostaglandin D2 
8. PGDH - 15-Hydroxyprostaglandin dehydrogenase 
9. PGE2 - Prostaglandin E2 
8. PGHS-1 Prostaglandin H synthase 1 
     9. PGHS-2 Prostaglandin H synthase 2 
10. PGI2 - Prostaglandin I2 or Prostacyclins 
11. PR - Progesterone receptor 
12. RNA – Ribonucleic acid 
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IEC APPROVAL 
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PATIENT CONSENT FORM 
STUDY TITLE: DROTAVERINE HYDROCHLORIDE VERSES 
HYOSCINE BUTYLBROMIDE IN AUGMENTATION 
OF LABOUR AMONG NULLIPAROUS WOMEN 
 
STUDY CENTRE:   RSRM lying in hospital, Chennai. 
 
PARTCIPANT NAME:  AGE:   I.D.NO: 
 
I confirm that I have understood the purpose of the above study. I have the 
opportunity to ask the question and all my questions and doubts have been 
answered to my complete satisfaction. 
 I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being 
affected. 
I understand that investigator, the institution, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
respect to the current study and further research that may be conducted in relation 
to it, even if I withdraw from the study. I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that 
arise from the study. 
I hereby consent to, undergo complete physical examination, and diagnostic tests 
including haematological, and ultra-sonogram examinations for me. 
I hereby consent to participate in this study on “DROTAVERINE 
HYDROCHLORIDE VERSES HYOSCINE BUTYL BROMIDE IN 
AUGMENTATION OF LABOUR AMONG NULLIPAROUS WOMEN”.  
 
 
 
Place:       Signature of the Patient:  
Date:       Address: 
Signature of the witness:    Signature of Investigator: 
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தகவல் படிவம் 
 ஸ்டான்லி மருத்துவமனையின் ஆர்.எஸ்.ஆர்.எம். 
மருத்துவமனையில் மகப்பேறு மற்றும் பேண்கள் நல மருத்துவ 
துனையில் பமற்பகாள்ளப்ேடும் ஆய்வு ப ாடர்ோை  கவல் ேடிவம் 
இது. 
 
 இந்  ஆய்வு அனுேவம் வாய்ந்  மருத்துவர்களின் உ விபயாடு 
நடத் ப்ேடுகிைது. 
 
 கர்ப்ேிணி பேண்களுக்கு ேிரசவ வலி ஏற்ேட்ட ேிைகு, ேிரசவம் 
வினரவாக நிகழ்வ ற்கும் ஊசி மூலம் ஒரு மருந் ினை பசலுத் ி 
அ ன் ஆற்ைனல கண்டைியும் ஆய்வு இது. 
 
 இ ன் மூலம் ேிரசவத் ின் போழுது ேிரசவத் ிற்காை பநரம் 
குனைகிைது என்ே னை ேல்பவறு ஆய்வுகள் கூறுகின்ைை. 
 
 எைபவ இந்  ஆய்வினை இந்  மருத்துவமனையில் கர்ப்ேிணி 
பேண்களுக்கு பமற்பகாண்டு ஊசி மூலம் டிராட்படாபவரின் 
(Drotaverine) அல்லது அபயாசின் (Hyoscine) என்ை மருந் ினை 
பகாடுத்து ேிரசவத் ிற்காை பநரம் குனைவதும், அ ன் மூலம் 
இம்மருந் ின் ஆற்ைலும், கண்டைியப்ேடுகிைது. 
 
 இந்  மருந் ிற்கு எந் வி  ேின்வினளவுகளும் இல்னல. 
 ாய்க்கும் பசய்க்கும் இந்  மருந்து ோதுகாப்ோைது. 
 
 இந்  ஆய்வு கர்ப்ேிணி பேண்கள்  ங்கள் சுய விருப்ேத்துடன் 
முன்வந் ால் மட்டுபம பமற்பகாள்ளப்ேடும். 
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ஒப்புதல் படிவம் 
 
 
திரு. /  திருமதி. .............................................................................................................. 
......................................................................................................................................................
......................................................................................................................................................
.................................................................................................................................... 
என்ற விலாசத்தில் வசிக்கும் நான், எனக்கு அளிக்கப்பட்ட தகவல் 
படிவத்தில் உள்ள விவரங்களள படித்தும், ககட்டும் புரிந்து 
ககாண்கடன். 
 
 இந்த ஆய்விற்கு கதளவயான சளதப் பரிகசாதளனக்கு உட்பட 
சம்மதிக்கிகறன். 
 
 ஆய்வின் முடிவிளன கசாந்த அளடயாளங்களள 
கவளியிடாமல் மருத்துவ ஆராய்ச்சிக்காக பயன்படுத்திக் ககாள்ள 
சம்மதிக்கிகறன். 
 
 
 
நாள் : ளககயாப்பம்  
 
இடம் : கபயர் 
 
 
                                                                                            Group A : CONTROL Group
1 min 5 min
1 Suganya 20 3730 Primi Y 180 60 VD 9 6 8 2.6
2 Vanitha 19 3839 Primi Y 190 70 VD 8 7 9 2.3
3 Muthelizh 26 3810 Primi Y 210 60 VD 8 6 8 2.5
4 Sugila 19 3823 Primi LSCS FD 7 8 2.7
5 Priya 24 3815 Primi Y 200 55 VD 8 6 8 2.5
6 Suganthi 29 3826 Primi Y 190 65 OVD ME 6 VL 7 9 2.5
7 Deepa 23 3841 Primi 250 50 VD 10 6 8 2.7
8 Gayathri 20 2639 G2A1 Y 270 70 VD 9 6 9 2.6
9 Poongodi 26 3847 Primi Y 230 55 VD 9 7 8 2.7
10 Ajemunisa 22 3890 Primi Y 195 60 VD 9 6 8 2.9
11 KavithaLakshmi 19 3855 Primi 190 70 VD 10 6 9 2.8
12 Rajalakshmi 23 3908 Primi Y 180 55 VD 8 PPH 7 8 3.1
13 Revathi 19 4134 Primi Y 240 60 VD 9 6 8 2.9
14 Anjali 19 4092 Primi 270 55 VD 10 7 8 2.6
15 Krishnaveni 19 4217 Primi Y 170 55 VD 9 6 8 2.7
16 Sivaranjini 23 4255 Primi Y 190 70 VD 9 6 8 3
17 Sindhuja 19 4261 G2A1 210 60 VD 9 7 9 2.6
18 Dharani 25 4243 Primi 170 60 VD 8 7 8 2.5
19 Sharmila 24 3772 Primi Y 195 55 VD 9 6 9 2.6
20 Indhumathi 21 3715 Primi LSCS FP 6 8 2.8
21 Divya 20 4396 Primi Y 200 55 VD 10 6 9 2.8
22 Jayachitra 21 4424 Primi 185 45 VD 9 7 8 3.7
23 Asha 23 4413 Primi Y 205 35 VD 8 6 8 2.6
24 Bina 21 4436 Primi Y 265 35 VD 10 6 9 2.7
25 Vinothini 21 4477 Primi 210 40 VD 9 6 8 2.6
26 Saranya 20 4185 Primi LSCS FP 7 8 3
27 Sumathy 19 4530 G3A2 195 60 VD 10 6 9 2.8
28 Vaitheeswari 19 4501 Primi Y 220 55 VD 9 6 8 2.9
29 Nagalakshmi 23 4541 G2A1 Y 235 50 VD 9 7 8 2.6
Duration 
of active 
phase 
(min)
Duration 
of II 
stage 
(min)
Mode of 
delivery(I
ndication)
S.N
o
Name Age IP No Obs Code Oxytocin Indication
Duration 
of  III 
stage 
(min)
Complication
Adverse  
  Effects
Birth 
weight 
(kg)
NICU 
APGAR
30 Afifa 20 4570 Primi 210 55 VD 10 6 8 2.4
31 Gayathri 19 4538 Primi Y 210 50 VD 9 7 9 2.6
32 Mumtaj 21 4739 Primi Y 250 55 VD 10 6 8 2.8
33 Sakila 22 4727 G2A1 Y 195 50 VD 9 7 8 2.8
34 Revathi 19 4219 Primi LSCS FD 6 9 3
35 Banu 25 4763 G2A1 Y 270 45 VD 9 7 8 2.8
36 Thilagavathy 19 4746 Primi Y 190 50 VD 10 5 8 2.8
37 Kavitha 20 4848 Primi 220 50 VD 9 7 9 2.8
38 Suganthi 19 4647 Primi 210 40 VD 10 6 8 2.9
39 Indhu 22 4847 Primi Y 250 60 VD 9 7 8 2.6
40 Yasmin 19 4681 Primi Y 210 55 VD 10 6 9 2.7
41 Manju 20 4928 Primi 205 55 VD 9 7 8 3
42 Sindhubairavi 20 4939 Primi Y 235 35 VD 10 6 8 2.8
43 Barathi 23 4945 Primi 225 60 VD 9 7 9 2.9
44 Durgadevi 21 4286 Primi LSCS FP 7 8 2.5
45 Ilavarasi 20 4920 Primi Y 195 30 VD 9 7 8 3.1
46 Devayani 19 4954 Primi Y 210 60 VD 10 6 9 2.5
47 Meena 22 4263 G2A1 LSCS FP 6 9 2.7
48 Senjamma 20 4954 Primi Y 200 50 OVD ME 9 7 8 3
49 Sahana 19 4878 G2A1 205 45 VD 9 6 9 3.2
50 Vaitheswari 23 4967 Primi Y 265 60 VD 9 6 8 2.8
51 Nandhini 32 5089 Primi Y 195 60 VD 10 7 9 3.2
52 Hemalatha 21 5058 Primi 240 50 VD 9 6 9 2.6
53 Venupriya 22 5124 Primi Y 215 60 VD 8 7 9 2.8
54 Nivedhana 21 4460 G2A1 LSCS FP 6 9 3.1
55 Selvi 20 5138 Primi 200 65 VD 9 7 8 2.6
56 Chandini 20 5148 Primi Y 205 55 VD 9 5 9 2.5
57 Poornima 19 4777 Primi 195 60 VD 9 7 8 2.9
58 Ayesha kath 21 5128 Primi Y 235 55 VD 8 7 8 2.6
59 Saranya 21 5158 Primi Y 240 50 VD 9 6 8 2.6
60 Lakshmi 27 5191 Primi Y 210 55 VD 9 6 9 2.7
61 Yogalakshmi 18 5353 G2A1 195 50 VD 9 6 8 2.9
62 Shayidha 19 5356 Primi Y 225 45 VD 9 7 9 2.4
63 Muniamma 22 5352 Primi 190 70 VD 8 6 8 2.9
64 Parameshwari 23 5359 Primi Y 210 60 VD 9 6 9 3.2
65 Sumithra 19 4940 Primi LSCS FD 6 8 3
66 Pavithra 18 5431 Primi Y 270 55 VD 10 6 9 3.1
67 Jabeenabegum 22 5402 Primi 190 45 VD 9 7 9 2.4
68 Thilagavathy 22 5395 Primi Y 195 55 OVD ME 10 7 8 2.5
69 Revathi 20 5414 Primi 270 30 VD 9 7 8 2.9
70 Sangeetha 19 5423 Primi Y 250 55 VD 10 7 8 3.3
71 Bhuvaneshwari 21 5164 Primi Y 270 50 VD 9 7 9 3.1
72 Kanmani 19 5415 Primi Y 200 35 VD 10 6 8 3
73 Ponni 24 5386 Primi Y 195 35 VD 6 PPH 7 9 2.6
74 Sampooranam 27 5396 Primi Y 175 40 VD 9 6 8 2.5
75 Ilavarasi 19 5647 Primi 190 50 VD 10 7 9 2.5
76 Varsha 29 5581 Primi Y 190 60 VD 9 6 9 2.7
77 Ammu 21 5614 Primi 200 70 VD 9 7 8 3
78 Jeeva 23 5654 Primi Y 195 60 VD 10 6 8 2.8
79 Vijayalakshmi 19 5665 Primi Y 205 40 VD 9 7 9 3.1
80 Jayanthi 20 5678 G2A1 Y 225 45 VD 10 6 8 2.5
81 Shabana 23 5608 Primi 200 40 VD 9 7 9 2.9
82 Vimala 19 5746 Primi Y 190 60 VD 9 6 8 3.1
83 Sangeetha 21 5752 Primi Y 210 70 VD 9 7 9 2.7
84 Jayalakshmi 20 5757 Primi Y 190 55 VD 9 6 8 3.2
85 Shanthi 21 5754 Primi 195 55 VD 8 7 9 2.5
86 Prema 19 5496 Primi LSCS FP 6 9 2.4
87 Riyana 29 5683 Primi Y 195 60 VD 10 6 9 2.6
88 Sangeetha 19 5799 Primi Y 200 60 VD 8 6 8 2.7
89 Divya 25 5807 Primi Y 205 60 VD 9 7 9 2.8
90 Aswini 22 5753 Primi 215 55 VD 9 6 8 2.6
91 Priya 23 5809 Primi Y 220 50 VD 8 7 9 2.7
92 Tamilselvi 23 5576 Primi LSCS FD 5 8 3.2
93 Divya 21 5855 Primi 195 55 VD 9 5 8 3 A
94 Nargis 19 5940 Primi Y 200 60 VD 9 6 8 2.4
95 Sangeetha 19 5972 Primi Y 205 70 VD 8 6 9 3.1
96 Banupriya 22 6001 Primi 210 55 VD 9 7 8 2.9
97 Kalaivani 19 5964 Primi 260 55 VD 10 6 8 2.5
98 Roja 21 5866 Primi Y 250 60 VD 9 7 9 2.8
99 Nandini 23 5997 Primi LSCS FP 7 8 3.1
100 Sindhu 21 5947 Primi Y 275 70 OVD FD 9 7 8 2.9
101 Sruthi 19 6175 Primi LSCS FP 6 8 3.4
102 Divyabarathi 21 6163 Primi Y 195 55 VD 9 7 9 4
103 Desamma 19 6205 Primi 265 70 VD 9 7 8 3.3
104 Padmavathy 24 6108 Primi Y 190 50 OVD FD 7 6 9 3
105 Durgadevi 19 6150 Primi Y 205 45 VD 9 7 8 3.6
106 Tamaraiselvi 24 6217 Primi 225 55 VD 8 6 9 3.2
107 Sangeetha 20 6214 Primi Y 250 80 VD 10 6 8 3
108 Kanimozhi 19 6157 Primi Y 190 60 VD 9 6 9 3.2
109 Javaharnisa 20 6259 G2A1 Y 195 70 VD 8 6 8 3.2
110 Suganthi carolin 20 6277 Primi 220 60 VD 9 6 8 3.1
111 Aruna 20 6087 Primi Y 250 55 VD 10 6 9 2.6
112 Ranjani 21 6287 Primi Y 195 60 VD 9 7 8 2.4
113 Theresa 19 6213 G2A1 LSCS FP 6 9 2.5
114 Mohanasundari 20 6206 Primi 240 55 VD 9 6 8 3.2
115 Sundari 20 6513 Primi Y 210 60 VD 9 6 9 2.8
116 Sandya 30 6500 Primi Y 200 55 VD 9 6 8 3.6
117 Priya 20 6506 Primi 225 50 VD 9 7 9 2.6
118 Zohara 18 6360 Primi Y 190 35 VD 9 6 8 3.1
119 Sangeetha 21 6201 Primi LSCS FD 7 9 2.9
120 Emima 19 6489 Primi Y 200 50 VD 9 7 8 2.7
121 Gnanasundari 23 6446 Primi 220 70 VD 10 7 8 3.2
122 Zeenathnisa 20 6505 Primi Y 270 45 VD 9 6 9 3.1
123 Arulselvi 27 6478 Primi 195 55 VD 10 7 8 2.6
124 Suganya 20 6488 Primi Y 190 50 VD 9 6 8 2.6
125 Mumtaj 20 6547 Primi Y 225 35 VD 8 7 9 2.6
126 Vimala 24 6764 Primi Y 235 40 VD 9 7 8 2.5
127 Sindu 20 6813 Primi 190 40 VD 10 6 9 3.7
128 Barakath 19 6778 Primi Y 210 55 VD 8 5 8 2.9
129 Karima 19 6156 Primi LSCS FP 7 9 2.5
130 Famitha 20 6689 Primi 205 55 VD 10 6 8 2.5
131 Kanagavalli 19 6614 Primi Y 195 35 VD 9 7 9 2.5
132 Jeevitha 22 6822 Primi Y 260 45 VD 9 7 8 3
133 Salomi 21 6793 Primi Y 215 40 VD 10 7 9 21
134 Divyabharathi 20 6743 Primi 220 50 VD 9 7 8 2.7
135 Valarmathi 19 6831 Primi Y 235 50 VD 8 7 9 2.5
136 Geetha 20 6591 Primi Y 220 55 VD 9 6 8 3.4
137 Malarvizhi 25 6829 Primi Y 195 45 VD 10 6 9 2.8
138 Sasikala 21 6847 Primi 200 60 VD 9 7 8 2.9
139 Shynaz 21 6838 Primi Y 180 60 VD 10 6 9 2.9
140 Janani 19 6785 Primi Y 200 45 VD 9 7 8 3
141 Polamma 18 6861 Primi 210 50 VD 10 6 9 2.9
142 Jothi 19 6747 Primi 195 55 VD 9 6 9 2.7
143 Sasikala 22 6920 Primi Y 260 45 VD 10 6 9 2.8
144 Nagalaksmi 21 6937 Primi Y 205 60 VD 9 7 9 2.6
145 Logeshwari 20 5082 Primi Y 190 75 OVD ME 10 VL 6 8 2.6
146 Mohana 22 6978 Primi 195 60 VD 8 6 8 2.5
147 Abirami 19 6981 Primi Y 200 50 VD 9 6 8 3.1
148 Ismathfathima 19 6974 Primi Y 255 50 OVD ME 10 6 8 3.1
149 Bhuvana 19 7041 Primi 220 50 VD 9 7 8 2.4
150 Hameethabee 22 7044 Primi Y 190 65 VD 9 7 9 2.4
151 Jothi 22 7039 Primi Y 250 50 VD 10 6 8 2.4
152 Sudha 21 7038 Primi 270 55 VD 8 6 8 2.5
153 Anandanayagi 21 7042 Primi Y 190 45 VD 10 7 9 2.4
154 Velvizhi 19 7014 Primi Y 195 55 VD 9 6 8 2.9
155 Sudha 27 6778 Primi Y 270 60 OVD ME 8 7 9 3
156 Syedalifathima 19 6940 G2A1 235 55 VD 9 6 9 2.6
157 Deepika 19 7026 Primi Y 225 60 VD 10 7 8 2.4
158 Jothilaksmi 20 7088 Primi Y 195 45 VD 9 6 8 2.8
159 Karpagam 27 7098 Primi 250 50 VD 9 6 8 3
160 Baby 20 7093 Primi Y 235 45 VD 10 7 9 2.7
161 Abirami 22 7096 Primi Y 210 40 VD 9 6 9 3.1
162 Deepa 25 7169 Primi Y 270 65 OVD FD 9 5 9 2.6
163 Revathi 19 7350 Primi 200 40 VD 10 6 8 2.6
164 Ambika 22 7380 Primi 210 50 VD 9 6 9 3.1
165 Gayathri 21 7407 Primi Y 190 55 VD 8 7 9 2.8
166 Sowmya 19 7417 Primi 200 50 VD 10 5 8 3 A
167 Vijayalakshmi 21 7397 Primi 195 40 VD 9 7 9 3.4
168 Kanimozhi 26 7428 Primi Y 200 45 VD 9 7 9 2.4
169 Chitra 23 7365 Primi Y 190 40 VD 9 7 8 2.6
170 Palaniammal 20 7431 Primi 210 60 VD 10 6 8 3
171 Varalakshmi 21 7576 Primi Y 250 55 VD 9 7 8 3.3
172 Anandhi 19 7557 Primi 195 45 VD 9 6 9 2.9
173 Priya 19 7417 Primi Y 200 50 VD 9 7 8 3.7
174 Kavita 19 7577 Primi Y 190 45 VD 10 6 9 3.2
175 Padmavathy 23 6483 Primi LSCS FP 7 8 3.6
176 Sindhu 20 7509 Primi 210 55 VD 9 6 9 2.8
177 Manimegalai 20 7618 Primi Y 195 60 VD 8 6 8 2.4
178 Seetha 23 7613 Primi 200 50 VD 9 6 8 2.6
179 Thatchayini 21 7660 Primi Y 210 45 VD 10 6 9 2.7
180 Vijayalakshmi 22 7670 Primi Y 195 55 VD 9 6 8 3.1
181 Renukadevi 19 7845 Primi 205 55 VD 8 7 9 2.3
182 Bhavani 18 7877 Primi 195 60 VD 10 6 8 2.7
183 Rosemary 21 7882 Primi Y 210 50 VD 9 6 9 2.6
184 Nandini 19 7467 Primi Y 190 55 VD 9 7 8 3.1
185 Gomathi 22 7887 Primi 265 55 VD 9 6 8 3.7
186 Mohana 20 7841 Primi Y 245 50 VD 10 6 9 2.9
187 Lakshmi 21 7901 Primi 235 55 VD 9 6 9 2.8
188 Naseema 21 7862 Primi Y 210 55 VD 8 7 8 2.5
189 Ramya 21 7839 Primi Y 195 60 VD 10 6 8 2.6
190 Raheema 21 7876 Primi 225 45 VD 9 7 9 2.7
191 Sowndariya 19 7955 Primi Y 200 55 VD 9 7 9 2.5
192 Shayinabegum 26 7935 Primi 190 60 VD 9 6 8 2.7
193 Saranya 19 8080 Primi Y 205 50 VD 9 7 8 2.8
194 Divya 19 8079 Primi 170 45 VD 10 6 9 2.8
195 Jayanthi 22 6520 Primi Y 265 70 OVD ME 8 VL 7 8 2.9
196 Amala 25 7964 Primi Y 180 55 VD 10 6 9 2.9
197 Dhanalakshmi 19 8049 Primi 200 50 VD 9 7 8 2.6
198 Manimozhi 18 8003 Primi Y 210 55 VD 9 6 9 2.5
199 Revathy 21 8093 Primi Y 190 50 VD 10 7 9 2.5
200 Aarthi 19 8114 Primi Y 250 55 VD 8 6 8 2.5
Y -Yes LSCS -Lower Segment Ceasarean Section ME -Maternal Exhaution MT-Maternal tachycardia H-headache
VD -Vaginal Delivery FP -Failure to Progress PPH -Postpartum Haemorrage N -Nausea P -Photophobia
OVD -Operative Vaginal Delivery FD -Fetal Distress VL -Vaginal laceration V -Vomitting A -Admission
                                                                                      Group B : DROTOVERINE Group
S.No Name Age IP No Obs Code Oxytocin
Duration 
of active 
phase 
(min)
Duration 
of II 
stage 
(min)
Mode of 
delivery  
/ 
Indication
1 Èswari 19 3940 Primi Y 170 55 VD
2 Monica 26 3973 Primi Y 230 60 VD
3 Parvathi 23 4004 Primi Y 180 50 VD
4 Bavani 28 3997 Primi 150 45 VD
5 Anita 23 4015 Primi Y 145 55 VD
6 Amuda 21 4022 Primi Y 170 45 VD
7 Pramila 20 4021 Primi 160 45 VD
8 Poorani 31 4026 Primi 190 30 VD
9 Riyana parveen 28 4055 Primi Y 160 40 VD
10 Kokila 28 4083 Primi Y 155 50 VD
11 Kamathchi 20 4395 Primi 250 70 OVD
12 Sheela 21 3998 Primi Y 170 55 VD
13 Banu 21 4047 Primi 210 45 VD
14 Ranjitha 19 4256 G3A2 Y 200 45 VD
15 Eswari 20 3833 Primi LSCS
16 Divyabharathi 23 4133 Primi Y 160 50 VD
17 Revathi 20 4404 G2A1 Y 150 45 VD
18 Amul 22 4414 Primi 150 55 VD
19 Kaliammal 19 4381 Primi Y 155 45 VD
20 Divya 20 4009 Primi LSCS
21 Banumathi 22 4214 Primi 155 45 VD
22 Gomathi 19 4545 Primi 140 40 VD
23 Priyanka 24 4544 Primi Y 200 35 VD
24 Ranju 22 4474 Primi Y 180 55 VD
25 Yasmin 19 4606 Primi 170 55 VD
26 Jayalalitha 28 4608 Primi 140 45 VD
27 Divya 31 4345 Primi Y 145 45 VD
28 Tamilselvi 27 4596 Primi 160 35 VD
29 Nandhini 19 4605 Primi 145 30 VD
30 Manjudilima 18 4591 Primi Y 180 55 VD
31 Anandhi 29 4616 G2A1 Y 220 45 VD
32 Durgadevi 24 4846 Primi Y 170 40 VD
33 Haseena 20 4747 Primi LSCS
34 Logeswari 19 4898 Primi 180 50 VD
35 Tamil ilakya 19 4896 Primi Y 170 45 VD
36 Nishanthi 20 4900 Primi Y 140 40 VD
37 Devika 19 4899 Primi 155 60 VD
38 Vijayalakshmi 20 4087 Primi LSCS
39 Bharathi 20 4879 Primi Y 150 40 VD
40 Vaishnavi 20 4902 Primi 155 55 VD
41 Shakila 25 4941 Primi Y 190 50 VD
42 Srilekha 20 4949 Primi 170 40 OVD
43 Dhanalakshmi 28 4966 Primi Y 155 55 VD
44 Queenmary 22 4976 Primi 160 45 VD
45 Valli 21 4960 Primi Y 170 60 VD
46 Thirumaniselvi 19 5029 G3A2 Y 160 45 VD
47 Suganya 27 4303 Primi LSCS
48 Sudha 24 5007 Primi 185 45 VD
49 Mary 18 4955 G2A1 Y 145 35 VD
50 Ilavarai 24 4360 Primi LSCS
51 Rajee 24 5115 Primi 150 55 VD
52 Shakira beevi 19 5142 Primi 160 50 VD
53 Angaleshwari 28 5217 Primi Y 155 45 VD
54 Lavanya 25 5229 Primi Y 190 50 VD
55 Nagarani 21 5136 Primi 140 55 VD
56 Devi 21 5211 Primi Y 150 50 VD
57 Anusuya 19 5123 Primi 160 45 VD
58 Ilavarai 31 5219 Primi Y 145 55 VD
59 Seetha 22 4536 Primi LSCS
60 Akila 21 5382 Primi 145 50 VD
61 Rajeswari 22 5438 Primi Y 145 55 VD
62 Banupriya 22 5422 Primi Y 160 50 VD
63 Balalakshmi 31 5449 Primi 165 50 VD
64 Sugumari 24 4995 Primi 155 55 VD
65 Migavathy 29 5441 Primi Y 160 45 VD
66 Gomathi 27 5470 Primi 160 50 VD
67 Sherin 19 4794 Primi LSCS
68 Sandya 20 5493 Primi Y 160 50 VD
69 Suganya 19 5494 G3A2 Y 160 60 VD
70 Mary jenifer 21 5446 Primi 165 45 VD
71 Latha 27 4997 Primi Y 210 50 OVD
72 Mohanavalli 21 5675 Primi Y 190 35 OVD
73 Priyanka 20 5696 Primi 155 55 VD
74 Saraswathi 19 5709 G2A1 Y 165 50 VD
75 Pavithra 18 5565 Primi Y 145 55 VD
76 Nandhini 21 5454 Primi 155 45 VD
77 Ayesha Begum 22 4715 Primi LSCS
78 Srisha 29 5702 Primi 150 55 VD
79 Mahalakshmi 21 5653 Primi Y 135 60 VD
80 Muthulakshmi 21 5710 Primi 145 55 VD
81 Sonidevi 19 5720 Primi Y 140 45 VD
82 Nivedha 19 5185 Primi 150 50 VD
83 Mahalakshmi 20 5794 Primi Y 160 35 VD
84 Parveen 21 5774 Primi 155 45 VD
85 Sasikala 25 5812 Primi Y 160 60 OVD
86 Saranya 19 5584 Primi 135 40 VD
87 Nalini 28 5668 Primi Y 155 30 VD
88 Priya 19 5834 Primi 160 45 VD
89 Gayathri 24 5255 G2A1 LSCS
90 Fathima 19 5640 Primi Y 145 55 VD
91 Maharajothi 19 5874 Primi 155 40 VD
92 Roselin 21 6096 Primi Y 180 45 VD
93 Poornima 22 6125 Primi Y 240 50 VD
94 Rasathi 22 6135 Primi 210 55 VD
95 Bavani 21 6118 Primi Y 155 45 VD
96 Chitra 27 6129 Primi 150 55 VD
97 Hemalatha 18 6141 Primi Y 160 45 VD
98 Sathya 22 5417 Primi LSCS
99 Kanaga 19 6147 Primi 175 55 VD
100 Nithya 21 6326 Primi Y 185 50 VD
101 Shakilabanu 19 6331 Primi 170 30 VD
102 Madhavi 21 6340 Primi Y 155 55 VD
103 Meena 19 6347 Primi 145 50 VD
104 Venkatalaksmi 18 6344 Primi Y 135 30 VD
105 Vasanthi 20 6346 Primi Y 160 40 VD
106 Vinothini 20 6360 Primi Y 145 55 VD
107 Meena 27 5828 Primi LSCS
108 Shyna 18 6329 Primi 155 45 VD
109 Farzana 20 6333 Primi Y 145 45 VD
110 Poojamary 20 6299 Primi Y 135 50 VD
111 Uma 19 6344 Primi 165 50 VD
112 Bhavani 24 5806 Primi LSCS
113 Shruthi 21 6358 Primi Y 170 50 OVD
114 Mohana 18 6357 Primi 145 55 VD
115 Anjalai 19 6348 Primi Y 155 45 VD
116 Dhanalakshmi 23 6338 Primi Y 145 40 VD
117 Radika 19 6396 Primi 170 55 VD
118 Nithya 18 6400 Primi 165 40 VD
119 Lavanya 21 6355 Primi Y 155 50 VD
120 Bhuvaneswari 19 6406 Primi Y 180 45 VD
121 Jothi 22 6345 Primi 165 60 VD
122 Sandya 20 6404 Primi 155 35 VD
123 Archana 20 6415 Primi Y 145 65 OVD
124 Durga 19 5708 Primi LSCS
125 Chitra 20 6432 Primi 165 40 VD
126 Samanthi 19 6699 Primi Y 150 45 VD
127 Sathya 26 6695 Primi Y 160 55 VD
128 Nandini 20 6688 Primi 155 45 VD
129 Sumithra 19 6579 Primi Y 160 50 VD
130 Chithradevi 22 6714 Primi 200 55 VD
131 Ranjitha 21 6711 Primi Y 150 60 VD
132 Manju 22 6771 Primi Y 160 55 VD
133 Aseena 21 6752 Primi 150 50 VD
134 Vinitha 19 6075 Primi LSCS
135 Kalki 18 6618 Primi Y 160 55 VD
136 Vijayalaksmi 21 6702 Primi Y 160 60 VD
137 Sangeetha 20 6766 Primi 170 55 VD
138 Seetha 22 6677 Primi Y 160 45 VD
139 Vijayalaksmi 19 6926 Primi Y 150 40 VD
140 Anandhi 18 6934 Primi 160 45 VD
141 Sowmya 21 6142 Primi LSCS
142 Muthulakshmi 21 6741 Primi Y 145 60 VD
143 Durga 19 6932 Primi 150 55 VD
144 Subha 21 6938 Primi Y 140 50 VD
145 Shakira 19 6718 Primi 155 60 OVD
146 Leela 19 6949 Primi Y 160 50 VD
147 Ammu 30 6200 G2A1 LSCS
148 Varmathi 24 6901 Primi 200 45 VD
149 Ilakiya 20 6945 Primi Y 160 35 VD
150 Priya 19 6963 Primi 155 55 VD
151 Ameena 19 6953 Primi Y 145 45 OVD
152 Divya 22 7025 Primi 165 40 VD
153 Manimegalai 23 7137 Primi 170 35 VD
154 Rajee 20 7030 Primi Y 165 40 VD
155 Sangeetha 18 6871 Primi Y 160 40 OVD
156 Meenatchi 24 7158 Primi 145 55 VD
157 Sangeetha 22 7108 Primi Y 150 50 VD
158 Priya 19 7142 Primi Y 160 50 VD
159 Jayanthi 21 6336 Primi LSCS
160 Rekha 23 7156 Primi 160 60 VD
161 Chandrabala 18 7422 Primi Y 170 60 VD
162 Archana 22 7460 Primi 160 65 VD
163 Kowsalya 20 7441 Primi Y 160 35 VD
164 Divyabharathi 19 7499 Primi Y 150 55 VD
165 Sangeetha 21 7138 Primi Y 145 60 OVD
166 Suriyakala 24 7396 Primi 160 45 VD
167 Gulnazbegum 25 7458 Primi 140 40 VD
168 Mahalakshmi 23 7554 Primi Y 155 35 VD
169 Rekha 18 7400 Primi Y 160 40 VD
170 Jansirani 18 7568 Primi 150 55 VD
171 Vijayashanthi 19 7569 Primi Y 190 45 VD
172 Bhuvaneswari 22 6355 Primi LSCS
173 Eswari 20 7672 Primi 175 55 VD
174 Umamaheswari 19 7832 Primi 145 50 VD
175 Thilagavathy 19 7680 Primi Y 160 45 VD
176 Tamilmozhi 19 7683 Primi 160 40 VD
177 Amulu 20 7723 Primi Y 155 55 VD
178 Monisha 19 7722 Primi Y 150 50 VD
179 Jothi 22 7644 Primi 160 45 VD
180 Vinothini 18 7735 Primi Y 145 35 VD
181 Amulu 21 7768 Primi 150 45 VD
182 Manjula 22 7933 Primi Y 130 50 VD
183 Chitra 20 7907 Primi 145 40 VD
184 Barbara 25 6436 Primi LSCS
185 Kokila 21 7865 Primi Y 155 65 VD
186 Umamaheswari 19 7894 Primi 160 60 VD
187 Muthubarathi 25 7808 Primi Y 200 45 VD
188 Bavani 20 7786 Primi Y 160 60 VD
189 Nalini 20 7327 G2A1 Y 170 55 OVD
190 Vinitha 19 7993 Primi 180 50 VD
191 Nagalakshmi 29 8017 G2A1 Y 160 50 VD
192 Tameena 22 7500 Primi 190 55 VD
193 Kalaiarasi 21 8096 Primi Y 210 45 VD
194 Chandanapriya 22 7942 Primi Y 140 45 OVD
195 Devi 28 8129 Primi Y 210 50 VD
196 Kanagavalli 20 8128 Primi 170 50 VD
197 Vijayalakshmi 20 7970 Primi Y 180 60 VD
198 Sudha 19 6898 Primi Y 200 55 OVD
199 Varalakshmi 19 8141 Primi 155 50 VD
200 Narmada 19 8137 Primi Y 165 45 VD
Y -Yes LSCS -Lower Segment Ceasarean Section ME -Maternal Exhaution
VD -Vaginal Delivery FP -Failure to Progress PPH -Postpartum Haemorrage
OVD -Operative Vaginal Delivery FD -Fetal Distress VL -Vaginal laceration
Indication
Duration 
of  III 
stage 
(min)
Complication
Adverse  
Effects APGAR
Birth 
weight 
(kg)
NICU 
1 min 5 min
9 6 8 3.3
10 7 9 2.5
9 6 8 3.1
10 6 9 3.2
10 7 8 2.9
9 7 8 2.6
8 6 9 2.6
10 6 9 2.5
8 7 9 3.3
9 6 8 2.8
ME 9 VL 6 8 2.9
9 7 9 2.9
10 7 8 2.6
9 6 9 2.6
FD 7 8 2.8
9 N 6 8 2.7
8 6 8 3.1
10 7 9 2.8
9 7 8 2.6
FP 7 8 3
9 6 9 2.9
8 6 9 2.5
9 6 8 2.8
8 7 8 3.3
10 6 8 3.2
9 6 9 2.9
10 6 8 2.7
8 PPH 6 8 2.7
8 MT 7 9 2.6
9 6 8 3.3
9 6 9 2.8
10 6 8 3.1
FP 5 8 2.6
9 6 9 2.9
10 7 8 3.7
8 6 9 2.6
10 7 9 2.8
FD 6 8 3.4
9 6 9 2.4
8 6 8 3.2
10 7 9 2.8
ME 9 VL 6 8 2.8
9 7 9 2.8
8 V 6 8 3.1
9 6 9 2.6
10 6 8 2.6
FP 6 9 2.5
8 7 8 2.7
9 6 9 2.7
FP 6 8 3.2
9 7 9 2.6
10 6 8 2.9
8 6 9 3
9 7 9 2.8
8 6 8 2.4
9 6 8 2.6
10 7 9 2.8
9 7 8 2.7
FP 7 9 3.2
9 6 8 2.8
8 6 8 3
9 MT 6 9 2.6
10 7 8 3
10 6 9 2.7
9 6 8 2.8
8 7 9 2.5
FD 5 8 3.1
9 7 9 2.8
8 6 8 2.9
9 7 9 2.5
FD 10 VL 6 9 3.2
ME 8 6 9 3.1
9 7 9 2.4
8 6 8 2.7
9 6 9 2.4
10 7 8 3.3
FP 6 9 2.9
8 7 8 2.7
9 6 9 2.7
10 7 8 2.9
9 6 9 2.8
9 6 8 3.2
8 7 9 3.2
10 7 8 2.7
FD 9 N 6 8 3
9 7 9 2.5
10 5 8 2.4
9 7 9 2.7
FD 7 9 3.6
9 6 9 2.7
8 7 9 2.7
9 7 9 2.8
8 5 8 2.5 A
8 6 9 2.8
10 6 9 2.9
10 PPH 7 9 2.9
9 6 9 2.6
FP 9 7 9 3.1
8 7 8 2.4
9 6 8 3
10 7 9 2.9
9 7 9 2.8
9 6 9 2.7
8 7 9 2.4
10 6 9 2.6
9 6 9 2.4
FP 7 8 2.7
9 6 8 2.4
10 7 9 2.7
8 6 9 3.3
9 7 8 2.9
FP 5 7 2.8
ME 9 6 8 3.5
8 7 9 2.8
10 6 8 2.5
9 6 9 2.5
9 6 8 2.4
10 6 9 2.5
9 V 7 8 2.4
8 6 9 2.4
9 6 8 2.4
10 7 9 2.5
FD 9 6 9 3.4
FD 5 8 2.5
9 7 8 2.9
10 6 9 2.6
9 7 8 3.1
8 6 9 3.1
9 7 9 2.9
10 6 9 2.4
9 7 9 3
9 6 9 3.1
10 6 9 2.6
FP MT 7 9 3.2
9 6 8 3
9 6 9 2.9
10 7 8 2.6
9 6 9 3
9 6 8 3.9
10 7 9 2.6
FP 6 8 3.5
8 5 9 3.5
10 7 9 3.4
9 7 9 2.8
ME 9 7 8 3.5
10 6 9 2.4
FP 6 9 3.6
10 V 7 9 3.3
9 6 9 2.7
9 7 9 3.1
FD 8 6 9 2.4
9 6 8 2.7
10 PPH 7 9 3
9 6 8 2.4
ME 8 6 8 3
10 6 9 2.4
9 7 8 2.4
9 6 9 2.5
FP 7 8 2.7
10 6 9 2.8
9 7 8 2.8
10 6 9 3.1
9 7 9 2.5
10 6 8 2.8
ME 8 7 9 3.1
9 6 9 2.4
9 7 8 2.9
10 6 8 2.8
9 7 9 2.5
10 7 8 2.6
9 7 9 2.9
FP 7 8 2.8
9 MT 6 9 3.1
10 7 8 2.4
9 6 8 2.7
9 6 9 3
10 6 8 3
9 7 9 2.7
9 6 8 2.4
10 7 9 3.5
9 V 6 8 2.4
9 PPH 7 9 3
10 6 9 2.4
FP 7 8 2.7
10 H 7 8 2.8
8 6 9 2.5
9 6 8 3
10 7 9 3.1
ME 9 6 8 2.8
8 6 9 2.6
9 7 8 2.9
10 7 9 3.2
9 7 9 2.8
FD 10 5 7 3.3 A
9 V 6 8 2.8
8 6 9 3.1
10 7 9 3.1
ME 9 VL 6 8 3.4
8 7 8 2.7
9 6 8 2.9
ME -Maternal Exhaution MT-Maternal tachycardia H-headache
PPH -Postpartum Haemorrage N -Nausea P -Photophobia
VL -Vaginal laceration V -Vomitting A -Admission
                                                                                             Group C : HYOSCINE Group
1 Anitha 26 3767 Primi Y 180 50 VD
Nirosha 24 3754 Primi Y 150 55 VD
3 Saraswathi 21 3901 Primi Y 200 45 VD
4 Jothika 24 3927 Primi 130 55 VD
5 Shameema 23 3894 Primi 115 60 VD
6 Sangeetha 24 3939 Primi Y 160 45 VD
7 Radha 21 3880 Primi Y 150 50 VD
8 Vanishri 22 3814 Primi LSCS
9 Junuka 18 3969 Primi Y 150 55 VD
10 Jayanthi 20 3977 Primi 130 35 VD
11 Sudha 24 3929 Primi Y 240 45 VD
12 Buvaneshwari 20 4068 Primi LSCS
13 Deepa 25 4332 Primi 210 60 VD
14 Sasikala 22 4342 Primi Y 270 55 VD
15 Bhuvaneshwari 22 4314 Primi Y 140 50 VD
16 Sridevi 21 4336 Primi 120 55 VD
17 Malar 27 4204 Primi Y 140 60 VD
18 Vennila 25 4347 Primi 130 55 VD
19 Rahamathnisa 27 4350 Primi Y 130 35 VD
20 Rajathi 25 4310 Primi 120 55 VD
21 Amulu 23 4111 Primi LSCS
22 Vanitha 22 4298 Primi Y 160 45 VD
23 Manju 27 4571 Primi 210 60 VD
24 Bowya 25 4595 Primi Y 180 70 VD
25 Rafiya 19 4593 Primi 150 55 VD
26 Vaitheeswari 19 4617 Primi Y 130 50 VD
27 Shabana 19 4367 Primi Y 120 50 VD
28 Gunasundari 22 4356 Primi 150 45 VD
29 Kanithamozhi 28 3950 Primi LSCS
30 Selvi 21 4116 Primi 165 50 VD
31 Sruthi 20 4632 Primi Y 210 60 VD
32 Sasikala 26 4638 Primi 180 55 VD
33 Mubina 20 4642 Primi Y 140 50 VD
34 Anandhi 20 4302 Primi LSCS
35 Soniya 22 4646 Primi 190 45 VD
36 Renuka 23 4707 Primi 150 40 VD
37 Subbulakshmi 19 4737 Primi Y 120 45 VD
38 Sarala 20 4731 G2A1 Y 150 40 VD
39 Selvi 22 4657 Primi 120 50 VD
40 Thamilarasi 19 4299 G2A1 LSCS
41 Kalpana 19 4958 Primi 200 50 VD
S.No Name Age IP No Obs Code Oxytocin
Duration 
of active 
phase 
(min)
Duration 
of II 
stage 
(min)
Mode of 
delivery
42 Jarina 21 4988 Primi 130 55 VD
43 Nagarani 21 5046 Primi Y 180 60 VD
44 Swathi 21 5067 Primi Y 135 40 VD
45 Rani 19 4408 Primi LSCS
46 Mohanapriya 26 5044 G2A1 120 45 VD
47 Karthika 23 5078 Primi Y 240 50 VD
48 Priya 20 5084 Primi 180 45 VD
49 Gowri 27 5071 Primi Y 120 60 VD
50 Fathimatabasu 31 5074 Primi 110 45 VD
51 Anjalidevi 19 5305 Primi 120 60 VD
52 Gayathri 24 5309 Primi 165 40 VD
53 Pattu 20 5304 Primi Y 150 55 OVD
54 Aruna 20 4409 G2A1 LSCS
55 Therasa 29 5311 G2A1 130 35 VD
56 Malathy 20 5301 Primi 150 50 VD
57 Nivedha 19 5322 Primi 136 55 VD
58 Nazreenbanu 23 5075 Primi Y 120 50 VD
59 Karpagam 20 5344 Primi Y 150 65 VD
60 Geetha 21 4687 Primi LSCS
61 Anitamary 22 5498 G2A1 120 50 VD
62 Megaraj 18 5495 Primi 170 50 VD
63 Sakilabanu 21 5541 Primi Y 180 60 VD
64 Meenakumari 29 5531 Primi Y 135 55 VD
65 Meena 24 5102 G2A1 LSCS
66 Irusamma 20 5520 G2A1 150 55 VD
67 Radhika 20 5509 Primi Y 170 45 VD
68 Megala 19 5463 Primi 150 50 VD
69 Manimegalai 20 5559 Primi Y 130 45 VD
70 Sangeetha 23 5547 Primi Y 180 50 VD
71 Priya 25 5370 Primi Y 190 75 OVD
72 Megala 25 5526 Primi 180 60 VD
73 Anusuysa 19 5527 Primi 135 48 VD
74 Nivedha 19 5637 Primi Y 130 55 VD
75 Yamini 23 5558 Primi Y 120 50 VD
76 Anandhi 19 5700 Primi 150 50 VD
77 Mangaleeswari 19 5691 G2A1 Y 180 60 OVD
78 Suvarthamma 21 5677 Primi Y 120 45 VD
79 Jamilabanu 19 5726 Primi 150 40 VD
80 Punitha 24 5725 Primi 115 35 VD
81 Nila 19 5854 G2A1 Y 130 55 VD
82 HummaHane 19 5841 Primi 130 50 VD
83 Revathi 19 5901 Primi 135 55 VD
84 Hameetha 19 5876 Primi Y 135 40 VD
85 Mohanapriya 21 5955 Primi Y 130 40 VD
86 Yasmin 20 5858 G2A1 130 35 VD
87 Kalpana 22 5554 Primi LSCS
88 Rajeswari 20 5956 G3A2 Y 100 55 VD
89 Sandya 20 5952 Primi 120 45 VD
90 Deepa 21 5975 Primi Y 130 50 VD
91 Suganya 21 5932 Primi 150 45 VD
92 Janani 20 5844 Primi Y 145 65 VD
93 Selvi 22 6060 Primi 170 70 VD
94 Sangeetha 19 5925 Primi Y 180 55 VD
95 Reshma 19 5888 Primi Y 125 50 VD
96 Alima 22 6059 Primi 130 40 VD
97 Hemavathy 21 5057 Primi Y LSCS
98 Priya 19 6025 Primi 150 50 VD
99 Munilakshmi 19 5979 Primi 135 55 VD
100 Thilakavathy 20 6092 Primi Y 180 60 VD
101 Dayalini 27 6030 Primi 160 45 VD
102 Bharathi 19 6084 Primi Y 135 55 VD
103 Iswariya 20 5692 Primi LSCS
104 Asha 19 6102 Primi 110 55 VD
105 Durgadevi 19 6211 Primi 160 60 VD
106 Komala 22 6422 G2A1 Y 190 50 VD
107 Lavanya 18 6341 G2A1 210 60 VD
108 Kalaivani 21 6450 Primi Y 120 55 VD
109 Hemalatha 21 6038 Primi LSCS
110 Preethi 20 6461 Primi 130 45 VD
111 Nithyasuba 23 6447 Primi Y 175 50 VD
112 Anitha 22 6334 Primi Y 130 50 VD
113 Rajeswari 20 6475 Primi Y 150 55 VD
114 Chithra 23 6332 Primi 120 60 VD
115 Sandya 22 6425 Primi Y 110 50 VD
116 Mala choudry 19 6010 Primi LSCS
117 Alageswari 21 6479 Primi 150 45 VD
118 Easwari 21 6476 Primi Y 115 50 VD
119 Bavani 22 6455 Primi 150 45 VD
120 Priya 19 6482 Primi Y 190 60 VD
121 Bavani 19 6507 Primi Y 180 55 VD
122 Malathy 23 6028 Primi LSCS
123 Senbapriya 26 6466 Primi 130 40 VD
124 Arunadevi 25 6557 Primi 135 45 VD
125 Krishnaveni 19 5865 Primi Y 125 40 VD
126 Ponmozhi 21 6594 Primi 130 30 VD
127 Bhuvaneshwari 19 6546 Primi Y 150 45 VD
128 Udayakumar 24 6070 Primi 115 35 VD
129 Zainabfatima 18 6630 Primi Y 135 40 VD
130 Sangeetha 19 6623 Primi 120 40 VD
131 Sundari 25 6645 Primi Y 190 60 VD
132 Durga 18 6636 G2A1 Y 115 40 VD
133 Bagiyalaksmi 21 6629 Primi 130 45 VD
134 Revathy 18 6621 Primi Y 130 45 VD
135 Indumathi 21 6686 Primi 135 35 VD
136 Neelu 22 6338 Primi LSCS
137 Masthani 19 6865 Primi 130 45 VD
138 Bhuvaneshwari 27 6895 Primi Y 130 45 VD
139 Revathi 19 6890 Primi 130 50 VD
140 Umamaheswari 19 6893 Primi Y 100 50 VD
141 Jeyakodi 25 6879 Primi Y 120 40 VD
142 Aruna 27 6801 Primi Y 130 45 VD
143 Jenifer 21 6874 Primi Y 150 60 OVD
144 Jamuna 19 6916 Primi 145 40 VD
145 Sharmila 26 6936 Primi 170 60 VD
146 Vinitha 20 6969 Primi Y 180 60 VD
147 Anandhi 22 6961 Primi 125 40 VD
148 Tangamani 19 6970 Primi 210 45 VD
149 Almaz 23 6330 Primi LSCS
150 Sathya 21 6933 Primi Y 110 45 VD
151 Rubini 21 7163 Primi Y 130 55 VD
152 Kavitha 19 7177 Primi 175 45 VD
153 Deepika 24 7144 G2A1 130 40 VD
154 Anbuselvi 20 7145 Primi Y 150 50 VD
155 Priya 20 7126 Primi Y 120 45 VD
156 Hemavathy 19 7264 Primi Y 110 40 VD
157 Gayathri 21 7267 Primi 130 60 VD
158 Preethi 21 7155 Primi Y 150 45 VD
159 Beula 20 7265 Primi 115 40 VD
160 Baby 22 7301 Primi Y 150 45 VD
161 Yamuna 29 5420 Primi Y 190 70 OVD
162 Mariswari 22 7263 Primi 180 60 VD
163 Umamaheswari 20 7265 Primi 130 45 VD
164 Divya 19 7324 Primi 130 45 VD
165 Babita 20 7249 Primi Y 135 40 VD
166 Menaka 27 7345 Primi Y 125 50 VD
167 Keerthika 19 7337 Primi 130 55 VD
168 Jeyalaksmi 20 7302 Primi Y 150 55 OVD
169 RidanaFathima 22 7356 Primi 170 45 VD
170 Subatra 20 7334 Primi 140 35 VD
171 Samsathbegum 20 7566 Primi Y 180 65 VD
172 Durga 22 7565 Primi Y 210 65 VD
173 Nazreen 19 7373 Primi 165 50 VD
174 Vinitha 20 6417 Primi LSCS
175 Kathijabegum 19 7742 Primi 150 40 VD
176 Radha 22 7734 Primi Y 120 50 VD
177 Syedalifathima 19 7744 Primi 130 45 VD
178 Sangeetha 24 7751 Primi Y 150 55 VD
179 Kalaivani 19 7754 Primi 230 40 VD
180 Meena 19 7743 Primi 160 50 VD
181 Selvambigai 25 7326 Primi Y 120 40 OVD
182 Jayalakshmi 19 7747 Primi 120 45 VD
183 Pratheeba 20 7726 Primi Y 130 45 VD
184 Nandini 21 7733 Primi Y 140 50 VD
185 Sasikala 22 7701 Primi 120 45 VD
186 Deepa 21 7803 Primi Y 140 35 VD
187 Shabana 21 6633 Primi Y 270 70 OVD
188 Mohana 22 7687 Primi 180 55 VD
189 Jeyalakshmi 21 7816 Primi 130 45 VD
190 Poornima 23 7832 Primi Y 150 45 VD
191 Devi 19 8187 Primi Y 180 45 VD
192 Dhanalakshmi 18 8139 Primi 150 50 VD
193 Kanmani 21 8190 Primi Y 115 40 VD
194 Sumathi 25 8200 Primi 130 45 VD
195 Sumathi 22 6736 Primi Y 200 60 OVD
196 Sundari 19 8131 G2A1 180 55 VD
197 Monika 22 8179 Primi 170 55 VD
198 Saraswathi 21 8133 Primi Y 130 45 VD
199 Chandraleka 20 8206 Primi Y 140 40 VD
200 Laksmipriya 21 8137 Primi Y 120 50 VD
Y -Yes LSCS -Lower Segment Ceasarean Section ME -Maternal Exhaution
VD -Vaginal Delivery FP -Failure to Progress PPH -Postpartum Haemorrage
OVD -Operative Vaginal Delivery FD -Fetal Distress VL -Vaginal laceration
Birth 
weight 
(kg)
1 min 5 min
9 6 8 3.1
10 7 8 2.8
10 6 9 2.6
8 MT 6 8 3.2
9 7 8 2.7
10 6 8 2.4
8 6 8 2.9
FD 7 9 3
8 7 8 3.6
10 PPH 6 8 3.3
9 6 9 2.5
FP 6 8 2.7
8 6 8 2.6
9 6 8 2.6
10 7 8 2.6
9 6 9 2.9
10 7 8 2.8
9 V 6 8 2.7
9 7 8 2.6
10 6 9 2.9
FP 6 9 2.7
10 7 8 2.8
9 5 9 2.7
9 7 8 2.9
8 6 8 3.2
10 7 9 3
7 6 8 2.8
9 7 8 3.1
FP 7 8 3.2
10 7 8 2.9
9 6 8 2.8
7 7 8 3.1
9 6 8 3
FD 5 8 3.2
9 7 9 2.7
8 6 9 2.8
10 6 8 2.6
9 7 9 2.8
9 6 8 2.6
FD 7 8 2.9
10 6 8 2.6
Adverse  
Effects
APGAR
NICUIndication
Duration 
of  
III stage 
(min)
Complicat
ion
9 6 8 3.2
8 7 8 2.6
9 6 8 2.6
FP 6 9 2.8
10 7 8 2.7
9 V 6 9 2.5
10 7 8 3.1
9 6 8 3.1
9 PPH 7 8 2.6
8 7 8 2.6
10 6 8 2.8
ME 9 6 8 3.1
FP 7 8 3.1
9 6 8 3
8 7 8 2.9
9 7 8 2.8
10 6 9 2.7
10 6 8 2.7
FD 5 8 2.8
8 6 8 2.5
9 7 9 2.5
10 6 8 2.6
9 6 8 3.5
FP 6 8 3.2
8 7 8 2.8
10 6 8 2.5
9 6 8 3.1
9 7 8 2.6
10 6 8 3.1
FD 8 VL 7 8 2.6
9 7 9 2.7
10 6 8 2.7
9 6 8 3.1
7 MT 6 9 3
9 7 8 2.8
ME 9 6 8 3
8 6 9 2.9
9 7 8 2.9
10 7 9 3.1
8 7 8 2.5
10 6 9 2.7
9 6 9 2.8
8 7 9 3.1
9 6 9 2.4
10 6 9 3.3
FP 7 8 2.8
8 6 9 2.6
9 6 8 2.6
9 7 8 2.7
10 6 8 2.8
8 6 8 3
9 7 8 3
10 N 6 8 3.5
9 7 8 2.7
9 6 9 2.7
FP 7 8 A
8 6 8 2.4
10 5 9 3
10 7 8 2.7
9 6 9 2.9
8 7 8 2.4
FD 5 8 2.7
9 MT 7 8 3
8 6 8 2.4
10 7 9 2.4
9 6 9 3.1
9 6 9 3
FP 6 8 2.8
8 7 8 2.4
10 V 6 8 3.1
9 6 8 2.9
9 7 8 2.5
8 6 8 2.9
10 6 8 2.8
FD 7 9 2.6
9 6 8 2.4
10 7 8 3.1
9 6 8 2.9
8 7 9 2.9
10 7 8 2.5
FP 7 9 2.8
10 6 8 3
9 6 8 3.4
10 7 9 2.6
8 6 8 2.7
9 7 9 3
10 PPH 6 8 3.6
8 6 9 2.5
9 7 9 2.4
9 6 9 2.9
10 7 8 3.2
8 6 8 2.4
9 7 8 2.6
10 7 9 2.9
FP 7 8 2.6
9 6 8 2.4
10 7 9 3
9 7 8 2.6
10 6 9 2.6
8 7 8 2.4
9 6 9 3.1
ME 10 7 8 2.4
8 6 9 2.6
9 7 8 2.8
9 6 9 3.3
8 7 9 2.8
10 6 8 3.3
FP 7 9 3.6
9 6 8 4
10 7 9 3.4
8 H 6 8 3.2
9 6 9 3.1
10 7 8 2.6
9 7 9 2.9
8 6 9 2.5
9 7 8 3.4
10 7 9 2.4
10 7 8 2.8
9 6 9 2.9
FD 8 VL 5 8 2.6 A
9 7 9 3.5
9 6 8 2.6
8 6 9 2.6
10 7 9 3
8 6 8 2.6
9 6 8 2.7
FD 10 7 8 3.1
9 6 8 3.1
8 P 7 9 2.4
9 6 9 2.4
10 6 8 2.6
9 7 8 3.4
FD 5 9 3.5
10 6 8 3.4
9 7 9 3.1
8 6 8 3.3
9 MT 6 8 2.6
9 7 8 2.6
9 6 9 2.5
ME 8 7 9 3.4
9 7 9 2.7
10 6 8 2.4
9 6 8 3.1
8 7 9 2.8
9 6 8 2.8
ME 9 VL 6 9 3.2
10 7 8 3
9 6 8 2.9
10 7 8 2.4
8 6 8 2.7
9 6 9 3
10 PPH 7 8 3.1
9 6 8 2.6
ME 8 6 8 3.5
9 6 8 2.7
10 7 9 3
10 6 8 2.5
9 6 8 3
10 7 8 2.8
ME -Maternal Exhaution MT-Maternal tachycardia H-headache
PPH -Postpartum Haemorrage N -Nausea P -Photophobia
VL -Vaginal laceration V -Vomitting A -Admission
